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Implications of primary cilia and associated lysophosphatidic acid signaling in 
glioblastoma biology and therapy. 
Yuriy Loskutov 
 
The primary cilium is a ubiquitous organelle presented on most human cells. It serves 
as a crucial signaling hub for multiple pathways including growth factor and G-protein 
coupled receptors. Loss of primary cilia was observed in various cancers, however, the 
implications of this event are unclear. Several studies show that loss of cilia promotes cell 
proliferation, suggesting that alteration of ciliary-dependent signaling can drive the hyper-
proliferative phenotype of cancer cells, therefore re-establishing primary cilia or targeting 
altered signaling pathways could be a beneficial strategy as an anti-cancer therapy. 
Glioblastoma (GBM) is one of the deadliest cancers with a median survival of 14 
months. Such rapid progression of the disease is usually due to the very high growth rate 
of the tumor and rapid recurrence after surgical resection. Current standard of care for 
GBM patients includes aggressive radiation and chemotherapy, thus there is a high 
demand for more targeted approaches. Primary cilia formation is drastically decreased in 
GBM, however, the role of cilia in glioblastoma proliferation has not been explored. The 
overall aim of this work was to elucidate the mechanisms of increases in proliferation 
driven by the loss of cilia, and utilize it to target GBM. The cellular origins of GBM are 
currently under debate. One of the potential candidates are astrocytes, a highly abundant 
type of cell in the brain. Loss of primary cilia in human astrocytes stimulates proliferation 
in the presence of serum. Lysophosphatidic acid (LPA) was found to be a serum 
component responsible for this phenotype. Lysophosphatidic acid receptor 1 (LPAR1), a 
G-protein coupled receptor, was found to be accumulated in primary cilium in both 
astrocytes and GBM cells when cilium was present, while previously reported interactors 
of LPAR1, Gα12 and Gαq, were excluded from cilium. LPAR1 signaling through Gα12/Gαq 
was previously reported to be responsible for cancer cell proliferation. Such 
compartmentalization in ciliated cells creates a barrier against unlimited proliferation, 
which is one of the hallmarks of cancer. 
Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated, 
highly proliferative astrocytes or GBM cells/xenografts drastically suppresses their growth 
both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles 
inhibited tumor progression in an intracranial glioblastoma patient-derived xenograft 
(PDX) model. Overall, in the current studies, a novel mechanism by which primary cilium 
restricts proliferation was established. Loss of primary cilia is sufficient to increase 
mitogenic signaling, and is important for the maintenance of a highly proliferative cancer 
phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict 
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1. Primary cilia: signaling hub/organelle/molecular machine 
1.1 Primary cilia structure, maintenance, and function 
Primary cilium is a non-motile, microtubule-based organelle. It is formed as a 
protrusion of a mature centriole in G1/G0, consists of nine doublets of microtubules known 
as an axoneme, and is covered with the plasma membrane (1) (Fig.1). Ciliary 
microtubules are built from tubulin α and β dimers with the “+”end located at the tip of the 
cilium. The axoneme includes a transition zone linking the cilium to the centriole/basal 
body, a doublet zone including both microtubule doublet A (full microtubule) and B (hemi-
tube), and a singlet zone where only A tubes are present (2). The base of the primary 
cilium usually emerges from an invagination in the cell plasma membrane known as the 
ciliary pocket (3). 
 
Figure 1. Principal components and organization of the primary cilium. 
Cilia accumulate multiple receptors and signal transduction components, thus tight 
regulation of ciliary trafficking is required. Indeed, an elaborate system of intraflagellar 
transport machinery exists, and the core components of this system are intraflagellar 
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transport (IFT) particles (Fig.1). IFT particles consist of motor proteins, IFT-A, IFT-B, and 
BBSome complexes (4). Motor proteins include heterodimeric kinesin II complex (KIF3A, 
KIF3B and KAP), homodimeric kinesin II complex (KIF17), and IFT dynein complex. 
Heterodimeric kinesin II is required for cilium assembly (5) and movement of the IFT 
particles along the doublet zone (6). Homodimeric kinesin II seems to be dispensable for 
cilium assembly (7) and is required for movement along the singlet zone of the axoneme 
(6). IFT-dynein propels the IFT particles from the tip of the cilium back to the cell body 
(8).Loss of IFT-dynein results in abnormal, bulging cilia with accumulation of the IFT 
particles at the tip (9, 10). IFT-A and IFT-B complexes form the core of IFT particles, 
however, the exact function and relation of their components are not clear (11). Several 
components, such as IFT88, were reported to be essential for cilium assembly (12). The 
BBSome complex derives its name from Bardet-Biedl syndrome, since mutations in its 
components cause this disease (13). The BBSome interacts with IFT-A and IFT-B 
complexes and is believed to participate in trafficking of the transmembrane proteins 
along the cilium (14). 
1.2 Mechanisms of assembly/disassembly of primary cilia 
Assembly of the primary cilium begins in G1 with a docking of the small cytoplasmic 
vesicles to the mother centriole, this is Cep164 and Talpid3-dependent event (15). The 
fusion of the small vesicles, which requires EDH1 and EDH3, generates a large ciliary 
vesicle encapsulating the growing axoneme (16). After the assembly of the large ciliary 
vesicle, Rabin 8 activates Rab8, which promotes cilium elongation (16). Elongation of the 
axoneme deforms the ciliary vesicle by creating two membrane surfaces: the sheath 
(outer membrane) and the shaft (membrane surrounding axoneme). After the docking of 
the mother centriole to the plasma membrane, the ciliary vesicle fuses with it, exposing 
the growing cilium to the extracellular environment (17). 
Disassembly of the primary cilium is a crucial event for cell cycle progression. As the 
cilium is a protrusion of the basal body, it anchors the centriole in the perimembrane area, 
thereby preventing it from participation in mitotic spindle formation (18). During the cell 
cycle, the cilium is assembled in the G1/G0 phase, fluctuates through S and G2, and gets 
disassembled during G2/M transition (19). It is not entirely clear what is the mechanism 
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of cilium disassembly, however, there are several lines of evidence suggesting complex 
regulation of this process. Activation of the mitotic kinase Aurora A (AURKA) is a key 
player in cilium disassembly, and inhibition or transient depletion of AURKA abolishes 
serum-initiated cilia disassembly. The scaffold protein NEDD9, also known as neural 
precursor cell expressed developmentally down-regulated protein 9, has been implicated 
in the activation of AURKA (20) and is required for cilium disassembly. Histone 
deacetylase 6 (HDAC6), an enzyme that deacetylates tubulin (21), is a known 
phosphorylation target of AURKA, which increases its deacetylase activity and 
destabilizes axonemal microtubules (19). Interestingly, the role of HDAC6 seems to be 
dispensable for cilia development, arguing that cilium can be disassembled without 
HDAC6 involvement (22). The microtubule-destabilizing kinesins KIF2A and KIF2C are 
potential candidates for direct disassembly of axonemal microtubules. Overexpression of 
both kinesins triggers cilium disassembly, and KIF2A activity towards cilia is regulated by 
polo-like kinase 1 (Plk1) (23). Plk1 is a well-known target of AURKA (24), and moreover, 
both KIF2A and KIF2C are known to be regulated by AURKA during mitosis (25, 26), 
which puts them in the same AURKA-driven pathway for cilium disassembly. Cell cycle 
related kinase (CCRK) and its substrates intestinal cell kinase (ICK) and male germ cell-
associated kinase (MAK) were reported to participate in cilium disassembly (27). 
Furthermore, CCRK has been implicated in Sonic Hedgehog (Shh) signaling and cilium 
length and morphology regulation (28). 
1.3 Primary cilia and signal transduction 
The complexity and evolutionary stability of the primary cilium suggest that it has some 
important functionality. For a long time, primary cilia was known for its role in Hedgehog 
signaling, making it indispensable for proper development. In mammalian cells, Shh 
receptor patched 1 (Ptch1) localizes to the primary cilium in absence of the ligand, and 
excludes the intermediate signaling molecule smoothened (Smo) from it. Protein kinase 
A (PKA) promotes proteolytic processing of Gli2/3 into a repressor form, thereby inhibiting 
Shh-driven gene expression. In the presence of Shh, Ptch1 translocates to the plasma 
membrane, and Smo moves into the cilium. This abrogates PKA activation, promoting 




Recently, several of the receptor tyrosine kinases (RTK) were reported to localize to 
the primary cilium, and signal in a cilium-dependent manner. Platelet-derived growth 
factor receptor (PDGFR) α was found to specifically accumulate in the primary cilium of 
fibroblasts, while PDGFRβ was excluded from the cilium. Engineered loss of the cilium 
induces rapid degradation of PDGFRα, and loss of its signaling ligand, PDGF-AA, while 
preserving signal transduction of PDGF-BB, a PDGFRβ-specific ligand (32). Insulin-like 
growth factor 1 receptor (IGF1R) is not exclusive to primary cilium, however, ciliary 
localization tends to sensitize it, as activation of the receptor upon stimulation was first 
detected in the cilium, and then spread further to the plasma membrane. Similarly to 
PDGFRα, loss of cilia drastically decreases ligand-induced activation of IGF1R and 
downstream phosphorylation of protein kinase B (AKT) (33). Other RTKs were also 
reported to localize to primary cilia, such as epidermal growth factor receptor (EGFR), 
which was found in cilia in kidney epithelial cells (34), astrocytes, and neuroblasts (35). 
Fibroblast growth factor receptor (FGFR) was reported to localize to motile cilia in the 
airways of rhesus monkeys (36), as well as to the basal body of primary cilia in mouse 
neural progenitor cells (37). Angiopoietin receptors Tie1/2 localize to primary cilia on the 
surface epithelium of the murine ovary, bursa, and extra-ovarian rete ducts (38). 
Unfortunately, the significance and role of cilia in these RTK signaling cascades are still 
unknown. 
Finally, a long list of receptors from the superfamily of G-protein coupled receptors 
(GPCR) was found to accumulate in the primary cilium of various cell types (39, 40). 
Several cilium-targeting sequences were identified within different types of GPCRs (41, 
42). Still, the importance of the cilium for GPCR signaling is very poorly understood. There 
is evidence suggesting that the cilium serves as a compartment to scaffold GPCR 
signaling components including adenylyl cyclases (AC) 3/5/6 and phosphodiesterase 4C, 
thus limiting the spread of downstream signaling (43). In addition to this, it has become 
evident that cilia can serve as a platform for GPCR signaling crosstalk through GPCR 
hetero-oligomerization (44) and downstream signaling modulation by co-localized 
receptors (45). In addition to these, a growing body of evidence indicates that the 
downstream effectors of GPCRs, heterotrimeric G-proteins, can also be accumulated or 
excluded from primary cilium. For example, Gαs is accumulated in cilia (46), as well as 
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Gαi2 and i3, while Gαi1 is excluded from it (47). Since GPCRs can usually interact with 
several types of Gα subunits, such compartmentalization creates a possibility for the 
cilium to act as a switch in GPCR signaling. 
1.4 Primary cilia loss/dysfunction associated diseases 
Mutations in cilium-associated genes can cause a plethora of diseases, collectively 
referred to as ciliopathies. Ciliopathies are systemic diseases with a wide variety of 
symptoms, usually including the development of abnormalities (polydactyly, situs 
inversus), vision loss, cyst formation in multiple organs, obesity, and neurological 
disorders (48). A classic example of a ciliopathy is Joubert syndrome (JBTS; 
MIM#213300). It is characterized by hypotonia, ataxia, psychomotor delay, an irregular 
breathing pattern, and distinctive cerebellar and brain stem malformations. Additional 
clinical features include retinal degeneration, cystic kidney disease, ocular colobomas, 
occipital encephalocele, hepatic fibrosis, polydactyly, and endocrine abnormalities (49). 
Another classic example is Bardet-Biedl syndrome (BBS, MIM#209900), which includes 
rod-cone dystrophy, polydactyly, obesity, learning disabilities, hypogonadism, and renal 
anomalies. Secondary features include speech delay or disorder, developmental delay, 
behavioral abnormalities, brachydactyly/syndactyly, ataxia/poor coordination/imbalance, 
mild hypertonia, anosmia, diabetes, fibrocystic liver disease, Hirschsprung’s disease, as 
well as dental and cardiovascular anomalies (50). Symptoms and clinical representations 
of ciliopathies are largely overlapping, and can be separated by developmental 
abnormalities such as polydactyly and situs inversus, which are usually associated with 
impaired Shh signaling, or by degenerative processes, such as retinal degeneration, and 
different manifestations of dysplasia. The latter is of particular interest, as it occurs 
through the whole life of the patient and manifests as cyst formation in the kidney (51) 
and liver (52). Interestingly, modeling loss of cilia usually produces a hyperproliferative 
phenotype in normal cells (53, 54), thus one may expect to see increased incidence of 
cancer in patients with ciliopathies. Unfortunately, no such data is currently available, 
however Birt-Hogg-Dubé syndrome, which is associated with an increased incidence of 




2. Primary cilia: potential target for anti-cancer therapy 
2.1 Primary cilia and cancer 
In multiple cancer types, cilia tend to be lost, however, the role of this event is not 
clear. Recent publications suggest that loss of cilia in cancer is a relatively early event in 
disease progression. For instance, a drastic decrease in ciliation can be observed in 
breast cancer at the stage of non-invasive ductal carcinoma in situ (56). The same 
observation holds true in prostate cancer. In preinvasive stage of prostatic intraepithelial 
neoplasia, the number of cilia is significantly decreased (57). In a mouse model of 
pancreatic cancer, loss of cilia was noted even earlier in pre-cancer lesions. In this model, 
pancreatic intraepithelial neoplasia of varying grades can be detected prior to tumor 
development, and in these lesions, cilia were already absent (58). On the other hand, a 
few reports claim that cilia may be needed for cancer progression in some cases. Since 
Shh signaling requires the primary cilium, cancer development in models driven by the 
activation of Smo was strongly inhibited by loss of the cilia, but if the driver was the 
activated form of Gli, then the cilia loss enhanced tumorigenesis (59, 60). So far, such 
observations have only been specific for Shh-driven tumors, which puts them on a list of 
peculiar exceptions from the general trend. 
So far, cilia loss seems to correlate with tumor progression and also perhaps, 
malignant transformation, but is it a driving force for the latter, or is it just a consequence 
of transformation? Modeling the loss of cilia in normal cells suggests that it promotes 
hyperproliferation in Shh-independent cells. Engineered loss of primary cilia promotes 
proliferation in the mouse dermis in vivo (54). In cell culture settings, deciliation of normal 
cholangiocytes was sufficient to increase the proliferation rate, and moreover, loss of cilia 
promoted attachment-independent growth (53). In the case of Shh-dependent cell 
populations such as neural stem cells, ablation of primary cilia seems to inhibit their 
proliferation and lead to hypocellularity (61, 62). This observation goes along with tumor 
models driven by Smo activation, where cilia are required for tumor initiation (59, 60). 
Several approaches have been made to restore primary cilia in cancer cells. In 
cholangiacarcinoma cells, depletion or inhibition of the protein HDAC6, which is 
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implicated in cilia disassembly (19), was found to robustly restore primary cilia and 
suppress proliferation (53). In glioblastoma cells, depletion of CCRK, which is also 
implicated in cilium disassembly, was found to significantly inhibit proliferation and restore 
ciliation. Interestingly, the number of ciliated cells increased up to 10% in this study, but 
depletion of protein KIF3A, which is required for cilia assembly, abrogated all effects of 
CCRK depletion on both ciliation and proliferation (27). 
Overall, in the majority of cancers, loss of cilia seems to be an early event associated 
with an increase in proliferation, and restoration of the cilia, even in small cell populations, 
drastically decreases the proliferative capacity of cancer cells. 
2.2 Glioblastoma and primary cilia 
GBM is one of the most fast progressing cancers, which has a median patient survival 
of 13-16 months (63). Currently, treatment options for GBM are very limited, with the 
standard of care including aggressive surgical resection, radiation therapy, and 
chemotherapy (64). Unfortunately, due to its high invasiveness and fast tumor growth 
rate, the majority of GBM patients present signs of recurrent disease within 32-36 weeks 
(65). There is therefore a very critical need for the discovery of new targets and the design 
of new therapeutic approaches to treat GBM. 
Recently, GBM was reported to have a drastically decreased ciliation rate. Only about 
10% of GBM cells can assemble cilia. Moreover, electron microscopy analysis of GBM 
biopsies showed that the few cilia that they do form possess multiple structural 
abnormalities (66-68). Further inhibition of primary cilia assembly in patient-derived GBM 
primary cell culture through the introduction of a dominant-negative variant of KIF3A 
seems to have a minimal and non-coherent effect on both cell proliferation in vitro and 
tumor growth in a mouse intracranial model (69). On the other hand, even minimal 
restoration of primary cilia seems to have a tremendous effect on cell proliferation (27). 
This clearly suggests that loss of cilia in GBM is a non-random event and may be 
associated with the high proliferative capacity of tumor cells. Understanding the 
mechanisms of cilia loss in GBM and which pathways lead to increased proliferation upon 
loss of the cilia will allow to devise new strategies to battle GBM. 
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3. LPA signaling in mammalian cells 
3.1 LPA production and function 
LPA (lysophosphatidic acid) is a water-soluble lipid metabolite with a wide variety of 
cellular functions. LPA promotes proliferation in fibroblasts (70), astrocytes (71), and 
multiple other cell types (72-77).In addition to proliferation, LPA promotes cell migration 
(76, 77), platelet aggregation (78), smooth muscle contraction (79), and neurite retraction 
(80), making it a versatile signal molecule. LPA is present in large amounts in serum (81), 
saliva (82), brain (83), and tumor ascites (84).For a long time, the biosynthesis of LPA 
was a mystery, but it is now known that there are two main pathways to produce LPA: 1) 
autotaxin (ATX), a secreted lysophospholipase D enzyme, converts 
lysophosphatidylcholine (LPC) into LPA (85), and 2) phospholipase A can produce LPA 
from phosphatidic acid (86). During development, LPA signaling participates in wound 
healing (87), blood and lymphatic vessel formation (88), and brain development (89). 
3.2 LPA receptors: expression and function 
LPA signals through a family of GPCRs known as lysophosphatidic acid receptors 1-
6 (LPAR1-6) (Fig.2). LPARs have distinctive expression patterns and functions. LPAR1 
is expressed in the heart, brain, placenta, skeletal muscle, kidney, pancreas, spleen, 
prostate, testis, ovary, small intestine, and colon (90). LPAR1 can interact with the 
heterotrimeric G-protein family members Gαi/o, Gα12/13, and Gαq/11 (91), and promote cell 
proliferation, migration, survival, and cytoskeleton rearrangements. LPAR1 knockout in 
mice can cause a reduction in body weight, minor craniofacial deformities, and increased 
neonatal lethality due to decreased suckling behavior (92). LPAR2 is expressed in the 
embryonic brain, testis, leukocytes, prostate, spleen, thymus, and pancreas (93). 
Predicted interactors of LPAR2 include Gαi/o, Gα12/13, and Gαq/11 G-protein family 
members. Surprisingly, LPAR2 knockout in mice did not reveal any gross abnormalities 
(94). LPAR3 is broadly expressed, interacts with Gαi/o and Gαq/11 G-protein family 
members, and its knockout in mice does not cause any severe gross abnormalities, 
however, multiple reproductive defects were observed in LPAR3 -/- females (95). LPAR4 
is distinct from LPAR1-3, being structurally close to P2Y purinergic receptors, and 
interacts with all four major classes of Gα proteins (91). Knockout of LPAR4 in mice 
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produces embryonic lethality caused by impaired vascular development (88). LPAR5 is 
also structurally similar to P2Y receptors, and interacts with Gα12/13 and Gαq/11 G-proteins. 
LPAR5-knockout mice display decreased nociception and behavioral abnormalities such 
as decreased anxiety, motivational changes, and reduced social exploration (96). LPAR6 
is the most recently discovered R2Y type of LPA receptor, which interacts with Gα12/13 
(97). Knockout of LPAR6 does not seem to cause any alterations in mice behavior or 
development, however, it does completely abrogate liver regeneration (98). So far, 
nothing is known about the regulation or subcellular localization of LPARs. 
 
Figure 2. Schematic of LPAR signaling. 
3.3 LPA/LPAR signaling in cancer 
Recently, it became evident that LPA signaling is involved in cancer development and 
progression. ATX, the major enzyme involved in LPA production, is highly expressed in 
multiple cancer types including neuroblastoma, hepatocellular carcinoma, breast cancer, 
renal cancer, and GBM (99). LPA promotes migration in a variety of cancers including 
pancreatic (84), prostate (100), breast (101), and GBM (102), as well as promotes 
proliferation (75). Mechanistically, LPA can activate multiple pathways inducing 
proliferation, potentially in cell type specific manner. In head and neck squamous cell 
carcinoma, LPA stimulation causes transactivation of EGFR (74), while in colorectal 
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cancer LPA promotes β-catenin pathway activation (75). In ovarian cancer, LPAR1 
requires Gα12 to sustain LPA-driven proliferation (72), and Gαq is required for normal 
intestinal epithelium proliferation (103). Depletion of LPAR2 significantly decreases 
colitis-associated colon cancer development, while LPA promotes it (104). In addition, the 
level of LPA can be used as a prognostic marker in ovarian and gastric cancers (105, 
106). Surprisingly, inhibition of LPA signaling is still poorly investigated as a therapeutic 
strategy against cancer, however, several works indicate that inhibition of LPAR1 with 
Ki16425 is sufficient to abrogate metastasis formation in breast cancer (107, 108) and 
inhibition of ATX increases radiosensitivity in GBM (109). 
4. Kinesin-13 family motors and their role in cancer 
4.1 Kinesin motor superfamily in regulation of microtubule dynamics 
The kinesin superfamily is a superfamily of motor proteins capable of moving along 
microtubules. Most kinesins target to the growing “+” end of microtubules, but there are 
several exceptions. The primary role of kinesins is believed to be the transport of different 
cargoes within the cell. The kinesin superfamily includes 16 families of proteins: kinesin-
1-12 possess a conserved N-terminal motor domain and move towards the “+” end of the 
microtubules (110-112), kinesin-13 family members have a motor domain in the middle 
and tend to disassemble microtubule lattice (113), and kinesin-14 family members have 
a C-terminal motor domain and move toward the “-“ end of microtubules (114). The 
kinesin-1, 2, and 3 families are involved in the trafficking of membrane-bound vesicles 
and organelles, while the kinesin-4, 5, 6, and 14 families function during mitosis and 
participate in spindle microtubule organization and chromosome tethering (115). The 
kinesin-8 and 13 families regulate microtubule dynamics by either inhibiting microtubule 
elongation or initiating disassembly. Kinesin-8 family members have increased 
processivity, promoting accumulation of the motors at the “+” end of long microtubules 
(116). At the “+” end, kinesin-8 family members can prevent the addition of new tubulin 
dimers to the lattice or can directly remove tubulin from microtubules; however, reports 
on the ability of kinesin-8 to directly disassemble microtubules are controversial (117). 
Kinesin-13 family members are directly implicated in microtubule disassembly. Their 
motor domain localizes in the middle of the protein, and by itself can destabilize 
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microtubules (118, 119), but their disassembly rate is significantly enhanced by the 
addition of the neck region, which directly precedes the motor domain (120-122). 
Mechanistically, kinesin-13 family members disassemble microtubules by bending tubulin 
protofilaments at the end of microtubules, locking them in an unstable conformation, and 
thus, initiating microtubule catastrophe (123, 124). 
4.2 Cellular function of kinesin-13 family members 
Kinesin-13 family members include KIF2A, KIF2B, KIF2C and KIF24 proteins (117). 
KIF2A is involved in mitosis and is required for bipolar spindle formation (125). It is also 
well known to be involved in brain development through suppression of axon branching 
and to be required for axon pruning (126, 127). It seems to be involved in the regulation 
of cytoskeleton remodeling during cell movement through interaction with Arf GAP using 
GTP-binding protein-like, ankyrin repeats and PH Domains1 (AGAP1), but the 
implications of this are still vague (128). KIF2B is poorly studied, but it is known to have 
a distinct function during mitosis (125). KIF2C is well known for its mitotic functions (125), 
and was shown to interact with EB1 and EB3 and target growing microtubules, suggesting 
potential participation in rapid tubulin cytoskeleton rearrangements (129). KIF24 
participates in the remodeling of centriole microtubules (130) and suppresses cilium 
assembly during mitosis (131). KIF2A and KIF2C were recently shown to be able to 
induce cilia disassembly (23). Surprisingly, both studies involved KIF24 and KIF2A/C and 
did not distinguish between the effects of the kinesin-13 family members on pre-formed 
cilia versus de-novo ciliogenesis. 
4.3 Kinesin-13 family members in cancer 
Recently, the potential involvement of kinesin-13 family members in cancer was 
highlighted in multiple publications. For instance, all of the kinesin-13 family members are 
associated with progression and poor prognosis of hepatocellular carcinoma (132). High 
expression of KIF2A can predict poor prognosis for diffuse large B-cell lymphoma (133) 
and gastric cancer (134), and it is associated with high-grade glioma (135). KIF2C was 
found to have strong prognostic value in renal clear cell carcinoma (136) and glioma 
(137), and was recognized as a potential anti-cancer drug target (138). The reason for 
such a strong association with poor prognosis of kinesin-13 family motors, particularly 
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KIF2A and KIF2C, is still elusive. However, several lines of evidence indicate that KIF2A 
expression is required for maintaining a highly proliferative phenotype and supporting 
migration in cancer cells (135, 139). The same observations were made for KIF2C (140, 
141). Moreover, depletion of KIF2A or KIF2C is sufficient to induce apoptosis in cancer 
cells (142) or to promote senescence (143). Interestingly, both KIF2A and KIF2C induce 
primary cilia disassembly (23), and even partial restoration of the primary cilia drastically 
inhibits cancer cell proliferation (27, 53). Thus it is tempting to speculate that KIF2A and 
KIF2C drive the loss of primary cilia in cancer cells. 
5. Aurora kinase A: master regulator of cilium 
5.1 AURKA structure and function 
AURKA is a mitotic serine/threonine kinase. The Aurora family of proteins consists of 
three known members: AURKA, AURKB, and AURKC. The N-terminal domain (1-128aa) 
of AURKA targets it to the basal body/centrosomes and allows it to interact with 
microtubules during mitosis (144). The N-terminal domain also inhibits the catalytic 
activity of AURKA when it is not bound to activating proteins (145) such as NEDD9 and 
TPX2. Activation of AURKA results in autophosphorylation of threonine 288 (activational 
phosphorylation) (19, 146-148) and serine 51 (protecting from degradation) (149). 
Inactivation of AURKA is regulated by protein phosphatase type 2a (PP2a) (150). Active 
AURKA is targeted to the centrosome through microtubule binding where it can function 
as a mitotic kinase. During mitosis, AURKA regulates the formation of 
Cdk1/CyclinB1complex through phosphorylation and activation of cdc25b phosphatase, 
which removes inhibitory phosphorylation from Cdk1 (151).Accumulation of AURKA is 
required for centrosome maturation and segregation (152). After nuclear envelope 
breakdown, AURKA is targeted to the mitotic spindle in complex with the microtubule-
binding protein TPX2 (146). Depletion of AURKA in normal cells results in G2/M arrest or 
the formation of a monopolar spindle, causing an inability to separate DNA and 
subsequent cell death (153). 
5.2 Role of AURKA in regulation of the ciliary dynamics 
Most AURKA studies focus on its role in mitosis and G2/M AURKA activation. 
Recently, a non-mitotic role of AURKA as a master-regulator of cilia disassembly became 
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evident. Serum stimulation of G1/G0-synchronized cells yielded activation of AURKA that 
was spatially restricted to the centrioles, and also cilia disassembly. In these settings, 
disassembly of the cilia occurs in two waves: first, within 1-2 hours after serum stimulation, 
and second, after 18-24 hours. The latter represents G2/M transition, but the first wave 
occurs during G1. Inhibition or depletion of AURKA completely abrogates the disassembly 
of cilia, while injection of the cells with pre-activated AURKA induces rapid deciliation (19). 
The exact mechanism of AURKA activation during the initiation of cilium disassembly has 
yet to be elucidated. However, several proteins participating in this event have already 
been established. Loss of NEDD9, a phosphorylation-independent AURKA activator, 
severely blunted cilia disassembly in response to serum (19). Calmodulin was shown to 
directly activate AURKA in a Ca2+-dependent manner, and binding to calmodulin is a 
prerequisite for serum treatment-induced cilia disassembly (154). Pitchfork (Pifo) also 
interacts directly with AURKA and promotes AURKA activation during cilia disassembly 
(155). 
 
Figure 3. Schematic of regulation of human KIF2C through phosphorylation. 
5.3 AURKA and KIF2C interface in mitosis and cilia 
KIF2A and KIF2C, microtubule-destabilizing kinesins, are potential candidates for 
direct disassembly of the cilia (23). During mitosis, AURKA regulates spindle targeting of 
both KIF2A and KIF2C, and interestingly, AURKA phosphorylation of KIF2A suppresses 
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its microtubule depolymerizing activity and suppresses spindle microtubules binding (25). 
KIF2C phosphorylation of serine 192 by AURKA can also suppress its depolymerization 
activity, however, the main effect of AURKA seems to be due to the phosphorylation of 
serine 719 (xenopus)/ 715 (human), leading to the redistribution of KIF2C to bipolar 
spindle microtubules (26). Plk1, a direct target of AURKA, can also phosphorylate serine 
715 and enhance depolymerization activity of KIF2C (156). In non-mitotic ciliated cells, 
overexpression of KIF2A or KIF2C initiates disassembly of cilia, but KIF2A was more 
potent (23). The observations were made in a serum-free media synchronized cell 
population, where AURKA is mostly inactive. Taking previously discussed data into 
account, activation of AURKA may drastically change the picture, since it will tend to 
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The primary cilium is a ubiquitous organelle presented on most human cells. It is a 
crucial signaling hub for multiple pathways including growth factor and G-protein coupled 
receptors. Loss of primary cilia, observed in various cancers, has been shown to affect 
cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), 
however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been 
explored. Here we report that loss of primary cilia in human astrocytes stimulates growth 
rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic 
acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through 
Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found 
that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against 
unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 
redistributes to the plasma membrane with a concomitant increase in LPAR1 association 
with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425 
in deciliated highly proliferative astrocytes or glioblastoma patient-derived 
cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, 
Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an 
intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism 
by which primary cilium restricts proliferation and indicate that loss of primary cilia is 
sufficient to increase mitogenic signaling, and is important for the maintenance of a highly 
proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to 





The primary cilium is a ubiquitous, microtubule-based organelle which is built on top 
of a membrane-anchored basal body. Primary cilium is an important negative regulator 
of proliferation and a key sensory organelle. It serves as a hub for multiple signaling 
cascades including receptor tyrosine kinase (1), Sonic hedgehog (Shh) (2), and G-protein 
coupled receptors (GPCRs) (3). Disassembly of primary cilium leads to release of the 
basal body, also called the mother centriole, which is required for mitotic spindle formation 
and mitosis. Multiple mitotic kinases initiate cilium disassembly including AURKA, Plk1, 
and Nek2 (4-6). Centrosome sequestration is considered one of the primary mechanisms 
of negative regulation of proliferation by primary cilium. Nevertheless, cilium shortening 
and disassembly is often observed immediately after growth factor stimulation in 
interphase (4). The role of this short-term disassembly in cell proliferation is currently 
unknown. Recent publications suggest that in different types of cancer including breast, 
prostate, renal, and glioblastoma (GBM), cilia tend to be lost (7-10). However, the 
importance of this event on tumor maintenance and progression or treatment is not well 
understood. 
Several studies report that loss of primary cilia in normal cells increases proliferation 
and supports attachment-independent growth (11, 12), which are common hallmarks of 
cancer. Attempts to restore primary cilia in cancer cells yield a significant inhibition on 
proliferation (12, 13). These observations suggest that cilia loss can promote/sustain a 
highly proliferative phenotype. However, in a subset of Sonic hedgehog (Shh)-dependent 
medulloblastomas, presence of cilium is mandatory (14) for cancer maintenance, 
therefore studies on specific cancer subtypes are warranted to establish cilia’s role in 
tumor biology and potential therapeutic applications. 
Astrocytoma is the most commonly diagnosed adult brain cancer (15), which often 
progresses to GBM. The majority of GBM patients succumb to the disease within 13-16 
months (15). GBM is a highly proliferative disease with limited treatment options (16). 
Lysophosphatidic acid (LPA) is an abundant mitogen in brain tissue (17). LPA acts 
through binding of heterotrimeric G-protein coupled receptors (LPAR1-6). It was 
previously reported that LPAR1 can signal through Gαi, Gα12, and Gαq family members 
(18, 19). LPA stimulates cell proliferation in astrocytes (20) and cancer cells (21). 
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Astrocytes are abundant glial cells and well known for their ability to proliferate, especially 
in the activated state (22), and were previously reported as the potential cells of origin for 
GBM (23). 
In our current work, we establish that loss of primary cilia promotes proliferation of 
primary non-transformed human astrocytes, providing permissive conditions for 
transformation in an LPA-dependent manner. GBM primary cells, with a decreased 
occurrence of primary cilia, were also sensitive to LPA and LPAR1/3 inhibition. 
Mechanistically, we found that LPA-LPAR1-driven mitogenic signaling was restricted in 
cells with primary cilium due to compartmentalization of LPAR1 and its downstream 
effectors, Gα12 and Gαq, in cilia and in cytoplasm, respectively. LPAR1 was redistributed 
to the plasma membrane upon loss of primary cilium, thus enabling its binding to Gα12 
and Gαq, and therefore suggesting that redistribution of LPAR1 is a key mechanism 
driving proliferation in a cilia-dependent manner. 
Inhibition of LPAR1/3 with the small molecule inhibitor Ki16425 significantly reduces 
cell growth rate only in deciliated astrocytes. Likewise, patient-derived GBM proliferation 
was stimulated by LPA and abrogated by Ki16425 in a dose-dependent manner. 
Importantly, the growth of GBM patient-derived xenografts in vivo was drastically 
decreased upon Ki16425 administration as a monotherapy without significant side effects. 
Taken together, our findings indicate that loss of primary cilia eliminates spatial 
barriers curbing proliferation, thus unlocking the potential for unlimited proliferation. LPA 
is one of the key mitogenic factors driving highly proliferative GBM with no or very low 
basal ciliation, therefore clinical interventions based on inhibiting LPA signaling may 





Loss of primary cilium promotes proliferation of astrocytes. 
Human astrocytes (HA) can form primary cilia. Incubation in serum-free media (SFM) 
promotes ciliation resulting in nearly 80% of cells having cilia (Fig.1A-B). This ciliation rate 
is similar to that observed in vivo (24). To allow for long term experiments, the primary 
human astrocytes (HA) were immortalized using SV40 large T antigen (HA-LTA) (25). 
Immortalization by LTA did not affect ciliation, which was similar to the parental astrocytes 
(Fig.S1A). To test how loss of primary cilia affects proliferation of primary (HA) or 
immortalized (HA-LTA) astrocytes, we utilized shRNA-driven knockdown of IFT88 or 
KIF3B, which are well characterized components of cilium assembly machinery (26, 27). 
Two shRNAs were used to target IFT88 or KIF3B resulting in up to a 90% knockdown 
(Fig1.C). Depletion of either IFT88 or KIF3B was sufficient to decrease ciliation to 5-15% 
(Fig.1D-E). These ciliation rates are similar to tissue biopsies from GBM patients (28). 
The loss of primary cilia resulted in a significant increase in growth rate of both 
immortalized and primary astrocytes (Fig1.F-G). Interestingly, this difference in growth 
rate was observed between ciliated (shCon) and deciliated (shKIF3B or shIFT88) cells 
only upon addition of serum-supplemented media (SSM), but not in SFM. Addition of SSM 
caused resorption of primary cilia in control cells in a biphasic wave pattern (Fig.S1B), 
which has been described previously for other cell types (4). These findings indicate that 
loss of primary cilia by itself does not promote proliferation, but rather increases the 
response to some mitogenic stimuli present in serum. 
 
Loss of primary cilia changes spatio-temporal response to mitogen stimulation. 
To elucidate the potential mechanism underlying cilia-dependent changes in cell 
growth rate, a time course analysis of synchronized (SFM starved) astrocytes was 
performed. Phosphorylation of ERK1/2 (Thr202/Tyr204) and AKT (Ser473), common 
readouts for a variety of mitogen and pro-survival stimuli, was used to follow the serum-
induced response. In agreement with previous reports, addition of 10% serum triggers a 
rapid (5-60min) increase in ERK1/2 and AKT phosphorylation followed by a gradual 
decrease (60-240min) in phosphorylation in all cell lines independent of ciliation status 
(Fig.2, Fig.3). Interestingly, the amount of phosphorylated ERK1/2 was twofold higher in 
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deciliated cells (shKIF3B or shIFT88) than in control (shCon) based on 
immunofluorescent and western blot assays (Fig.2A-F). Contrary to ERK1/2, 
phosphorylation of AKT was twofold lower in deciliated cells than in control (Fig.3A-F), 
indicating that changes in the pattern and intensity of the signal initiation/propagation act 
in a cilia-dependent manner. 
 
Lysophosphatidic acid signaling is critical for increased proliferation in 
deciliated astrocytes. 
To define the mitogene/s potentially responsible for the hyperproliferative phenotype 
of deciliated astrocytes, charcoal-stripped serum was used. Charcoal stripping is an 
efficient way to deplete bioactive lipids, as well as hormones and some vitamins (29), but 
preserve protein-based growth factors. Surprisingly, charcoal-treatment of serum (cSSM) 
was sufficient to completely abrogate the increase in growth rate observed in deciliated 
astrocytes (Fig.4A). One of the most abundant lipid-based mitogens found in serum is 
lysophosphatidic acid (LPA), which binds to LPA receptors (LPARs) to elicit a response. 
To test if LPA is involved in deciliation-dependent stimulation of proliferation, a small 
molecule inhibitor of LPAR1-3, Ki16425 (30), was used. Similar to cSSM, addition of 
Ki16425 to SSM was sufficient to abrogate the deciliation-dependent increase in growth 
rates, without any effect on growth of ciliated astrocytes (SSM vs. SSM+Ki16425) 
(Fig.4B). Moreover, addition of LPA alone to the serum-free medium (SFM) was sufficient 
to stimulate proliferation of astrocytes, and partially recapitulate the difference observed 
between ciliated and deciliated cells in the presence of serum (Fig.4B). As expected, LPA 
addition resulted in a pattern of ERK1/2 and AKT phosphorylation similar to the one 
observed during serum stimulation (Fig.4C-E). Surprisingly, treatment with EGF, bFGF, 
PDGF-A/B, or HGF as single agents was neither sufficient to induce proliferation 
(Fig.S2A) nor able to recapitulate the difference in phosphorylation of both ERK1/2 and 
AKT (Fig.S2B-C, Fig.S3A-B) previously observed between ciliated and deciliated cells 
(Fig.2E, Fig.3E). Interestingly, addition of a cocktail of protein growth factors (GFs) 
including EGF, bFGF, and B27 supplement along with LPA was sufficient to fully 
recapitulate the phenotype observed with addition of serum (Fig.4F). These findings 
indicate that LPA signaling is responsible for the highly proliferative phenotype observed 
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in astrocytes with disrupted ciliogenesis, but it requires additional growth factors to amplify 
its effect. 
 
LPAR1 localizes to primary cilia. 
To understand the mechanisms underlying cilia-dependent action of LPA, the 
subcellular localization of LPARs and Gα subunits participating in downstream signal 
transduction pathways was analyzed. A panel of LPARs fused with 3xFLAG-tag was 
exogenously expressed in astrocytes followed by immunofluorescent analysis using anti-
FLAG antibodies. LPAR1 and LPAR3, but not LPAR6, were consistently localized in 
primary cilium (Fig.5A, S4A-B). Interestingly, in deciliated cells, both LPAR1 and LPAR3 
were targeted to the plasma membrane (Fig.S5A-B). To exclude the possibility of 
overexpression-driven cilium targeting of LPAR1, we validated several anti-LPAR1 
antibodies for immunofluorescent staining, using CRISPR-Cas9 driven LPAR1 depleted 
astrocytes as a control (Fig.S6). Utilizing validated antibodies we were able to confirm 
that endogenous LPAR1 localizes to primary cilium when it is present (Fig.S7). 
Analysis of the cellular localization of multiple Gα subunits shows that only Gαs 
consistently targeted to primary cilia, similar to previous reports (31). However, whether 
other Gα subunits enter primary cilia is currently unknown. We found that Gαi1, Gαq, and 
Gα12 did not display ciliary localization, but rather diffuse cytoplasmic and plasma 
membrane staining (Fig.5C). Such a pattern of compartmentalization suggests that 
LPARs may engage in interactions with different Gα subunits depending upon presence 
or absence of primary cilia. 
 
LPAR1 directly binds to Gα12 and Gαq subunits in deciliated cells. 
To test this hypothesis, immunoprecipitation analysis was performed in shCon, 
shIFT88, and shKIF3B astrocytes transiently overexpressing 3xFLAG-LPAR1. Based on 
sequence similarity, LPAR1 is predicted to interact with Gαi, Gαq, and Gα12 (19). No 
interaction was detected between LPAR1 and Gαs. The robust co-immunoprecipitation of 
Gα12 and Gαq with LPAR1 was noted, being 2-3 times higher in deciliated astrocytes 
(Fig.5D). Previously, LPAR1 was reported to promote cancer cell proliferation specifically 
through Gα12 (18). Gαq was also reported to transmit pro-proliferative signals in cancer 
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(32). We concluded that LPAR1 is sequestered in primary cilia, which prevents its 
interaction with cytoplasmic Gα12 and Gαq, restricting its proliferative signaling. Loss of 
cilia promotes LPAR1 interaction with Gα12 and Gαq, thus promoting the proliferative 
response to LPA (Fig.5D). 
 
LPA signaling drives GBM proliferation both in vitro and in vivo. 
To evaluate our findings in disease-relevant settings, previously characterized GBM 
patient-derived cells and xenografts (33, 34) of two molecular subtypes (classical-GBM6 
and mesenchymal-GBM12) were used. In agreement with previous reports (28), only 5-
10% of GBM cells in vivo (GBM xenografts in mice, Fig.S8A-B) or in vitro (primary cells 
short term cultures, Fig.S8C-D) possess primary cilia. LPAR1 staining in GBM6 and 12 
cells shows similar pattern to primary astrocytes (Fig.S8E). LPA was previously 
implicated in GBM progression and invasiveness (35), hence its effects on GBM cell 
proliferation was evaluated. Upon addition of LPA in serum-free GF-supplemented media, 
a significant increase of primary GBM cell growth rate in vitro was observed (Fig.S8F), 
while addition of the LPA inhibitor, Ki16425, to SSM decreases GBM cell growth rate in a 
dose-dependent manner (Fig.S8G). 
Similar to in vitro studies, daily intraperitoneal administration of 30mg/kg Ki16425 as 
a monotherapy over 4-5 weeks significantly decreased the growth of subcutaneously 
transplanted GBM xenografts in immunodeficient mice (Fig 6A-E). In agreement with in 
vitro PDX cell line proliferation data (Fig.S8G), the number of mitotic figures in Ki16425-
treated tumors (Fig 6D, E) was twofold lower. Overall, these findings indicate that LPA is 
an important mitogen in GBM and inhibition of LPA signaling is a viable option to improve 
anti-GBM therapy. 
 
PEG-PLGA Ki16425 loaded nanoparticles slow down GBM growth in brain. 
To assess the feasibility of targeting GBM with Ki16425 in patients, its effect on GBM 
growth was evaluated in an intracranial mouse model. Preliminary studies indicated that 
the regimen used for the subcutaneous GBM PDX experiment was not efficient in the 
intracranial model (Fig.S9A-B), suggesting that Ki16425 is not capable of crossing the 
blood brain barrier. To overcome this issue, we used a PEG-PLGA nanoparticle-based 
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delivery system (36) to allow for robust Ki16425 brain entry. Fluorescently labeled 
nanoparticles rapidly entered the brain upon IP injection and were gradually 
excreted/degraded over the next 12h period (Fig.S9C-D).To account for this decay, the 
regimen was modified to 30mg/kg Ki16425 loaded into nanoparticles and delivered every 
12h. Mice were intracranially injected with 5x105 GBM12 cells and tumor growth was 
monitored weekly via MRI. Upon tumors reaching 5mm3, mice were randomly assigned 
to Ki16425 or a vehicle loaded nanoparticles control group. Over 2 weeks of treatment, 
the Ki16425 nanoparticle-treated group showed a twofold decrease in tumor progression, 
compared to control (Fig.7A-B). In agreement with our previous experiments, the number 
of mitotic cells was decreased twofold (Fig.7C-D). These findings show that Ki16425 with 
a proper delivery method can significantly suppress GBM progression, and potentially, in 






Primary cilium is well known for its role in multiple signaling cascades (1, 2, 11). 
Primary cilia length and the number of cells with cilium is significantly reduced or lost in 
multiple cancer types including GBM (7-10). Moreover, several studies have noted an 
increase in cell proliferation upon loss of primary cilia (11, 12). The proposed mechanism 
of cilia-driven proliferation control involves the sequestration of basal body (mother 
centriole) and the inability to form the mitotic spindle (37). Previously, it was shown that 
primary cilium disassembly is biphasic: a first wave of fast, transient disassembly within 
1-2h after exposure to mitogenic stimuli (4), followed by a second wave of disassembly 
at 18-24h, which coincides with mitotic entry. The role of the first wave of cilium 
disassembly in mitogenic signaling is currently unknown, as is the mechanism/s 
underlying the increase in proliferation upon loss of primary cilia. 
Several pro-proliferative signaling cascades are reported to require primary cilium for 
proper signal transduction. For instance, PDGF-AA signaling through PDGFRαα is lost in 
deciliated fibroblasts, therefore stimulation with PDGF-AA does not cause ERK1/2 or AKT 
activation (38); however, the overall proliferation effect of cilia loss was not evaluated in 
this work. SHH signaling is well-studied in conjunction with primary cilium. Loss of cilia 
ablates SHH signaling and Shh-driven proliferation (39), and correspondingly, Shh-driven 
cancers have a tendency to maintain high ciliation rates (14, 40). On the other hand, 
ciliary localization of IGF1R (41) and Notch (11) signaling is needed for differentiation and 
restriction of cell proliferation. Importantly, cilium can selectively sequester signaling 
components like GPR88 (42) and LPAR1/3 (Fig.5, S4) from their interaction with cilia-
excluded co-factors, thus conferring selectivity on signal propagation/amplification 
through the lateral segregation of receptors. This strongly argues that the effect of primary 
cilia on proliferation is context-dependent, with pro-proliferative effects during 
development through Shh signaling and anti-proliferative effects in more differentiated 
cells. 
In GBM, the complete inhibition of ciliogenesis seems to have minimal and non-
coherent effects on overall proliferation and tumor progression (43). Nevertheless, 
ciliation compared to normal brain cells is drastically decreased (9), supporting an anti-
mitogenic function of primary cilium in GBM. Our current findings suggest that the 
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engineered loss of primary cilia in normal human astrocytes phenotypically closely mimics 
transient cilium disassembly (Fig.S1B), and also resembles cilia loss in GBM cells 
(Fig.S8B, D). The increase in growth rate observed in deciliated cells (Fig.1F, G) suggests 
that transient cilia disassembly may be a key event augmenting mitogenic signaling. 
Mechanistically, we found that loss of primary cilia in human non-transformed astrocytes 
results in the amplification of ERK1/2 phosphorylation and promotes proliferation in an 
LPA-dependent manner (Fig.2, Fig.4). Interestingly, phosphorylation of AKT in response 
to LPA or serum stimulation was decreased in deciliated astrocytes (Fig.3). This can be 
attributed to inactivation of PDGFRαα (38) and IGF1R (41) driven signaling, and adds to 
the understanding of increased stress sensitivity in deciliated astrocytes (44). These 
findings support the idea that loss of primary cilia changes the pattern of the cellular 
response to mitogen stimulation, resulting in higher, more sustainable ERK1/2 activation 
thus explaining the increase in proliferation, but revealing the potential vulnerability of 
deciliated cells to stress via a decrease in pro-survival signaling (pAKT). Since GBMs 
usually have high pAKT levels (45) and we did not observe the transformation of deciliated 
astrocytes, we conclude that additional hit/s such as those well-known for GBM including 
RTK amplification/PTEN inactivation/PI3K activation, are required for overcoming the 
decrease in AKT activation. 
Previously, LPA was implicated in the regulation of cell migration and proliferation (21, 
35), however, the role of primary cilia in these signaling pathways was not explored. The 
LPA receptors (LPAR1/3) are specifically localized to primary cilium, but the LPAR 
downstream effectors, Gα12 and Gαq, are excluded from it (Fig.5, S4). Both Gα12 and Gαq 
activation is known to be implicated in cancer cell proliferation and cancer progression 
(46, 47). For Gα12, activation through LPAR1 specifically was reported in ovarian cancer 
cells (18). Our findings support the notion that in the absence of primary cilia, LPAR1 
localizes to the plasma membrane and interacts with Gα12 and Gαq (Fig.5D, S5, S7). 
However, further research is required to pinpoint the intracellular compartment for Gα12 
and Gαq and endogenous LPAR1 interaction. Hence, loss of primary cilia could be 
responsible for increased proliferation in a subset of cancers, and thus cilia restoration or 
the manipulation of cilia-dependent signaling such as LPA could be used to develop new 
therapeutic approaches to fight cancer. 
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GBM cells seem to be highly dependent on LPA as a mitogen, since inhibition of LPA 
signaling with Ki16425 abrogates their growth in vitro, and in both subcutaneous and 
intracranial GBM models (Fig.S8, Fig.6, Fig.7). Interestingly, the magnitude of the 
Ki16425 effect was the same between two in vivo models (Fig.6, Fig.7), suggesting that 
LPA signaling is equally engaged in both of them. LPA is known to be highly abundant in 
brain (3.7-35 pmol/mg) and serum concentration of LPA was reported to be close to this 
range (4-15.5 µM) (17). In addition, GBMs were reported to increase LPA production by 
secreting autotaxin (48). However, further studies are required for comprising the LPA 
levels in GBM PDXs grown in subcutaneous versus brain settings. 
GBM6 and GBM12 used in the current study are of classical and mesenchymal 
molecular subtypes respectively, and are highly aggressive in mouse models (33, 34). 
Both of these subtypes are associated with rapid disease progression and poor 
prognosis. Our in vivo experiments clearly show that targeting LPA signaling yields a 
twofold reduction of tumor growth, specifically through a decrease in the proliferation rate 
of tumor cells (Fig.6, Fig.7). Moreover, utilizing a PEG-PLGA nanoparticles delivery 
system confirmed the effectiveness of targeting LPA signaling in intracranial settings. The 
median survival of GBM patients with the current standard of care including aggressive 
surgery, radiation, and chemotherapy (49) is about 12 months (15), with the majority of 
patients experiencing recurrence within 32-36 weeks (16). Targeting LPA signaling can 
prove to be highly beneficial in addition to standard care, since LPA is implicated in 
proliferation and migration/invasion (21, 35). Further studies are required, but based on 
our findings, we expect a substantial increase in recurrence-free survival upon inhibition 
of LPA signaling. 
Overall, our data supports the role of LPA signaling in cancer cell proliferation, and for 




Materials and Methods 
Cell lines and reagents 
Human astrocytes isolated from human cortex (1800) were obtained from ScienCell 
Research Labs and maintained in DMEM/F12, supplemented with 10% heat-inactivated 
FBS, Antibiotic-Antimycotic (ThermoFisher) and 10 μg/ml of gentamycin (MP 
Biomedicals). Cells were propagated and cryopreserved at passage 2, for all studies cells 
were not passaged more than 10 times or 8 weeks, no authentication or mycoplasma 
testing were performed. For immortalization, primary astrocytes at passage 5 or 6 were 
cultured until 50–75% confluency and transfected with SV40 large T-antigen construct 
(25), followed by selection with 500μg/ml G418 (Sigma) until resistant colonies were 
formed. GBM6 and 12 PDXs (33) were kindly provided by Dr. Jann Sarkaria (Mayo Clinic, 
Rochester, MN) through a shared MTA agreement, no authentication or mycoplasma 
testing were performed. PDXs were maintained and used for intracranial injections or 
primary cell culture isolation as previously described (34). A list of antibodies and their 
used applications is outlined in Table S1. shRNA constructs were obtained from 
Dharmacon and are outlined in Table S2. All primers were purchased from IDT 
Technologies or Invitrogen, the sequences of which are reported in Table S3. The 
following reagents were used: Lysophosphatidic acid (LPA, Cayman Chemical), EGF and 
PDGF-AB (Sigma), HGF (R&D Technologies), bFGF (Peprotech), B27 supplement 
(ThermoFisher), Ki16425 (ApexBio). For lysophosphatidic acid stimulation experiments, 
bovine serum albumin (BSA; BP1600, Fisher Scientific) was used as a carrier and was 
added to all cells to a final concentration of 0.1%. 
 
Western blotting 
Western blotting was performed using standard procedures (50). Primary antibodies 
used are outlined in Table S1. Secondary anti-mouse and anti-rabbit HRP-conjugated 
antibodies (Jackson ImmunoResearch Labs) were diluted 1:10,000 followed by 
chemiluminescence-based detection with HyGLO™ (Denville Scientific). Bands were 
quantified using the digital electrophoresis documentation and image analysis software 





Immunofluorescent cell analysis  
Cells were processed as previously described (4). Primary antibodies used are 
outlined in Table S1. Secondary antibodies included AlexaFluor 488, 555, and 647 
(ThermoFisher). Images were captured using a standard setting by an LSM510 confocal 
microscope (Zeiss) (50). All images represent whole-cell 3D reconstructed projections 
with 0.4μm steps. All quantifications were done using ImageJ (NIH). 
 
Cell growth/proliferation analysis 
Cell growth rate was determined using semi-automated cell counting in ImageJ (NIH). 
Cells were plated at 1x104 cells per well and grown in the specified conditions for five 
days, fixed with methanol, and stained with Hoechst33342. Four random 10x fields per 
well were analyzed with at least three replicates per independent experiment; each graph 
represents at least three independent experiments. 
 
Fluorescent immunohistochemistry (F-IHC) 
Deparaffinization and rehydration of 4-5µm thin sections was performed as following: 
1) three times for 3 min in xylene, 2) three times for 2 min in 100% ethanol, 3) 2 min in 
95% ethanol, 4) 2 min in 80% ethanol, 5) 2 min in 70% ethanol, and 6) 5 min in 1XTBS. 
Antigen retrieval was done using 98°C citrate buffer, pH 6.0 for 20 minutes. Sections were 
blocked for 60 min with 5% BSA, 1XTBS solution and stained with the indicated primary 
antibodies. Secondary antibodies included AlexaFluor-488, 555, and 647 (ThermoFisher) 
and sections were mounted with ProLong Gold DAPI-containing media (ThermoFisher). 
Images were captured using LSM510 confocal microscope as previously described (50) 
(Zeiss). All images represent whole-cell 3D reconstructed projections with 0.4µm steps. 
All quantifications were done using ImageJ (NIH). 
 
LPAR cloning 
For robust expression and detection of LPARs, pcDNA3.1 vector was modified as 
previously described (51). Briefly, the insert containing the cleavable ER-targeting 
sequence followed by a 3xFLAG-tag and multiple cloning site (Table S3) was synthesized 
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through String™ service (ThermoFisher) and cloned into pcDNA3.1 between HindIII and 
SalI restriction sites. LPAR1, 3, 6 cDNA was amplified from a Human Mammary Epithelial 
Cells (HMECs) cDNA library kindly provided by Dr. Alexey Ivanov (West Virginia 
University, Morgantown, WV); primers are shown in Table S3. The generated inserts were 
cloned into pcDNA3.1 ER-3xFLAG between BamHI and XhoI restriction sites. All 
constructs were validated by sequencing. 
 
Immunoprecipitation 
For LPAR1 immunoprecipitation, 3xFLAG-LPAR1 was transiently overexpressed in 
cells pre-incubated for 24h in serum-free media. Cells were lysed as previously described 
(52). 3xFLAG-LPAR1 was precipitated with anti-FLAG M2 affinity gel (Sigma) and used 
for subsequent Western blot analysis. 
 
Animal experiments 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient male mice (The Jackson 
Laboratory) were housed in the West Virginia University Animal Facility under pathogen-
free conditions with an approved Institutional Animal Care and Use Committee protocol. 
For subcutaneous injections, 100µl of GBM6 or GBM12 tumor mash mixed 1:1 with 
Matrigel (Corning) was injected into the mice flanks. For intracranial injections, transient 
primary cell cultures were established as previously described (34), and 5x105 cells in 5µl 
of Ca/Mg-free Dulbecco modified Phosphate Buffer Saline (DPBS) were administrated 
into the mouse cortex via stereotactic device-guided injection (34). Subcutaneous tumor 
growth was assessed weekly via caliper measurements; treatment was initiated upon 
tumor volume reaching 100mm3. Intracranial tumor volume was assessed weekly via 
contrast enhanced MRI (53) or twice a week via bioluminescence imaging (54); treatment 
was initiated upon tumor volume exceeding 5mm3. Animals were randomly assigned to 
the treatment group by simple randomization, investigator was single blinded during 
group allocation. Mice bearing subcutaneous tumors were intraperitoneally injected with 
30mg/kg Ki16425 in 95% corn oil/5% DMSO or vehicle alone daily. For the intracranial 
model, mice were administered 30mg/kg Ki16425 loaded into PEG-PLGA nano-particles 
in PBS or given nano-particles alone twice daily. All animals were euthanized upon 
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reaching a moribund condition, according to the WVU IACUC Tumor Development and 
Tumor Scoring in Rodents policy. 
 
Contrast enhanced Magnetic Resonance Imaging (MRI) 
To visualize the intracranial tumors, mice were intraperitoneally injected with 
gadolinium-DTPA (contrast reagent, BioPAL) to a final concentration of 2mmol/kg (55), 
and imaged with a compact MRI system (ICON, Bruker). Images were taken with T1 
weighted RARE sequence (echo time: 26.23ms; repetition time 1984.158ms; averages: 
8; rare factor: 6). Overall time of scan was 25min and final resolution was 0.125mm for 
all axes. Stack images were reconstructed and analyzed using ImageJ (NIH). 
 
Animal bioluminescence imaging 
Mice were imaged twice a week for quantitative evaluation of tumor growth as 
previously described (56). Images were obtained using the IVIS Lumina-II Imaging 
System and Living Image-4.0 software (PerkinElmer). 
 
PEG-PLGA nano-particles 
Nano-particles were prepared as previously described (36). Briefly, PEG-PLGA and 
Ki16425 were dissolved in acetone and added dropwise into water. The nano-particles 
were stirred for 2 h at 40°C before being collected by centrifugation (4000g for 90 min). 
After discarding the supernatant, the nanoparticles were resuspended in Phosphate-
Buffered Saline (PBS). 
 
Statistical analysis 
Statistical comparisons were made using two-tailed Student’s t-test. When more than 
two groups were analyzed, one-way or two-way analysis of variance (ANOVA) was used. 
P<0.05 was considered to be significant (*) as indicated in figure legends. All treatment 
groups were compared to vehicle/control unless mentioned otherwise. Experimental 
values were reported as the means with +/-S.E.M (standard error of mean). All 
calculations of statistical significance were made using GraphPad software. Sampe sizes 
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and statistical analysis chosen were based on our previous experience and 
recommendations of biostatistician (4, 50, 56).  
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Fig. 1. Loss of primary cilia promotes astrocyte proliferation in a growth factor-
dependent manner. 
(A) Representative image of the cilium formed by primary human astrocyte (HA), 
stained for acetylated α-tubulin (AcTub, cilium marker) and γ-tubulin (γTub, basal body 
marker); scale bar – 10μm. (B) Quantification of primary astrocytes forming cilium, as in 
(A), in regular serum-supplemented media (SSM) or upon 48h of serum starvation (SFM); 
300 cells, 100 cells in each of 3 independent experiments; Student’s t-test, p<0.05. (C) 
Western blot of IFT88 and KIF3B in primary and immortalized astrocytes (HA-LTA) stably 
expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B. (D, E) 
Quantification of primary astrocytes (D) and immortalized astrocytes (E) forming primary 
cilium, as in (B) upon depletion of IFT88 or KIF3B, as in (C); 300 cells, 100 cells in each 
of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (F, 
G) Growth rates of primary astrocytes (F) and immortalized astrocytes (G) upon depletion 
of IFT88 or KIF3B in full media or in serum-free conditions (SFM); 3 independent 
experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. 
 
Fig. 2. Loss of cilium promotes increased ERK1/2 phosphorylation in response 
to serum stimulation. 
(A) Experiment schematics (top) and representative images of cells stably expressing 
non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B, stained for acetylated α-
tubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body marker), and ERK1/2 
phosphor-T202/Y204 (pERK1/2) ; scale bar – 10μm. (B, C, D) Quantifications of ERK1/2 
phosphor-T202/Y204 intensities in whole cells (B), nuclei (C) and cytoplasm (D) as in (A); 
100 cells in 3 independent experiments; two-way ANOVA with Dunnett’s post hoc test, 
p<0.05. (E) Representative western blot analysis of cells as in (A), stained for ERK1/2 
phosphor-T202/Y204, total ERK1/2, and GAPDH. (F) Quantifications of ERK1/2 
phosphor-T202/Y204 bands intensities, as in (E). 
 




(A) Experiment schematics (top) and representative images of cells stably expressing 
non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B, stained for acetylated α-
tubulin (AcTub), γ-tubulin (γTub), and AKT phosphor-S473 (pAKT) ; scale bar – 10μm. 
(B, C, D) Quantifications of AKT phosphor-S473 intensities in whole cells (B), nuclei (C) 
and cytoplasm (D) as in (A); 100 cells in 3 independent experiments; two-way ANOVA 
with Dunnett’s post hoc test, p<0.05. (E) Representative western blot analysis of cells as 
in (A), stained for AKT phosphor-S473, total AKT, and GAPDH. (F) Quantifications of AKT 
phosphor-S473 bands intensities, as in (E). 
 
Fig. 4. Lysophosphatidic acid promotes proliferation in deciliated astrocytes. 
(A) Growth rates of immortalized astrocytes stably expressing non-targeting shRNA 
(Con) or shRNA against IFT88 or KIF3B in serum-supplemented media (SSM), media 
supplemented with charcoal-stripped serum (cSSM), or in serum-free conditions (SFM); 
3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (B) 
Growth rates of cells as in (A) in serum-supplemented media (SSM), serum-
supplemented media supplemented with 10μmol/L Ki16425, serum-free media 
supplemented with 1μmol/L LPA (SFM LPA), or in serum-free conditions (SFM); 3 
independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (C) 
Experiment schematics (top) and representative western blot analysis of cells as in (A) 
stained for ERK1/2 phosphor-T202/Y204, total ERK1/2, AKT phosphor-S473, total AKT, 
and α-tubulin. (D) Quantifications of ERK1/2 phosphor-T202/Y204 bands intensities, as 
in (C). (E) Quantifications of AKT phosphor-S473 bands intensities, as in (C). (F) Growth 
rates of cells as in (A) SSM, SFM supplemented with 20ng/ml EGF, 20ng/ml bFGF, and 
B27 supplement (SFM-GF), SFM supplemented with 20ng/ml EGF, 20ng/ml bFGF, B27 
supplement and 1μmol/L LPA (SFM-GF LPA), or in serum-free conditions (SFM); 3 
independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. 
 
Fig. 5. Intracellular localization of LPA signaling cascade components. 
(A) Representative images of immortalized astrocytes expressing exogenous 
3xFLAG-LPAR1/LPAR3/LPAR6, stained for acetylated α-tubulin (AcTub, cilium marker), 
γ-tubulin (γTub, basal body marker) and FLAG-tag, arrowheads indicate primary cilium; 
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scale bar – 10μm (B) Representative images of immortalized astrocytes stained for 
acetylated α-tubulin (AcTub), γ-tubulin (γTub), Gαs, Gαq, Gα12 and Gαi1, arrowheads 
indicate primary cilium; scale bar – 10μm. (C) Immunoprecipitation of 3xFLAG tagged 
LPAR1 expressed in immortalized astrocytes stably expressing non-targeting shRNA 
(Con) or shRNA against IFT88 or KIF3B in serum-free conditions. (D) Schematic of 
potential mechanism of primary cilium restrictive action on the proliferative component of 
LPA signaling. 
 
Fig. 6. Inhibition of LPA signaling suppresses proliferation of GBM PDXs in vivo. 
(A) Representative images of mice subcutaneously injected with GBM6 (left panel) 
and GBM12 (right panel) and administered with vehicle or 30mg/kg/day Ki16425. (B, C) 
Analysis of tumor growth as in (A) for GBM6 (B) and GBM12 (C); 5 mice per group; two-
way ANOVA with Sidak’s post hoc test, p<0.05. (D, E) Analysis of GBM6 (D) and GBM12 
(E) terminal tumor weight; 5 tumors per group; Student’s t-test, p<0.05. (F, G) 
Representative images of GBM6 (F) and GBM12 (G), stained with DAPI; arrowheads 
indicate mitotic cells; scale bar – 20μm. (H, I) Quantification of mitotic figures as in (F, G) 
for GBM6 (H) and GBM12 (I); at least 1000 cells within 10 random fields per group; 
Student’s t-test, p<0.05. 
 
Fig. 7. Targeted brain delivery of Ki16425 suppresses GBM PDX growth in an 
intracranial model. 
(A) Representative MRI images of mice bearing intracranially grafted GBM12 
throughout the treatment with PEG-PLGA nanoparticles loaded with Ki16425 (30mg/kg 
twice a day); scale bar – 5mm. (B) Analysis of tumor growth as in (A); 5 mice per group; 
two-way ANOVA with Sidak’s post hoc test, p<0.05. (C) Quantification of mitotic figures 
as in (D); at least 1000 cells within 10 random fields per group; Student’s t-test, p<0.05. 
(D) Representative images of tumors from (A), stained with DAPI; arrowheads indicate 

























Supplementary Materials and Methods. 
Generation of CRISPR-Cas9 driven LPAR1 knock out in astrocytes. 
sgRNA targeting LPAR1 were designed using Broad institute web tool: 
https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design; synthesized as 
separate oligo nucleotides and cloned into pLentiCRISPR v2 (1) (a gift from Feng Zhang 
(Addgene plasmid # 52961)). Lentiviral particles were produced as previously described 
(2). Immortalized astrocytes were infected and selected on 1 µg/ml of puromycin until 
stable clones were formed. Individual cloned were established and tested for LPAR1 
expression. 
 
1. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for 
CRISPR screening. Nature methods. 2014;11(8):783-4. 
2. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-



































company application dilution 
acetyated 
alpha tubulin 
T6793 mouse Sigma IF, F-IHC 1:1000 
acetyated 
alpha tubulin 
5335S rabbit Cell Signaling IF 1:500 
gamma tubulin sc-7396 goat Santa Cruz IF, F-IHC 1:500 
IFT88 60227-1-Ig mouse Proteintech WB 1:1000 
Kif3B sc-50456 rabbit Santa Cruz WB 1:500 
alpha tubulin 16199 mouse Sigma WB 1:40000 
pERK1/2 
T202/204 
9101 rabbit Cell Signaling IF, WB 1:200, 1:1000 
ERK1/2 4695 rabbit Cell Signaling WB 1:1000 
GAPDH MAB374 mouse Millipore WB 1:80000 
pAKT S473 AF887 rabbit R&D Systems IF, WB 1:100, 1:500 
AKT 2920 mouse Cell Signaling WB 1:1000 
FLAG F1804 mouse Sigma IF, WB 1:500, 1:1000 
FLAG PA1-984B rabbit 
Thermo Fisher 
Scientific 
IF, WB 1:500, 1:1000 
G alpha s sc-135914 mouse Santa Cruz IF, WB 1:100, 1:500 
G alpha q sc-393 rabbit Santa Cruz IF, WB 1:200, 1:1000 
G alpha 12 sc-409 rabbit Santa Cruz IF, WB 1:100, 1:200 
G alpha i1 sc-391 rabbit Santa Cruz IF, WB 1:100, 1:500 
Arl13b 17711-1-AP rabbit Proteintech IF, F-IHC 1:400, 1:200 
LPAR1 20442-1-AP rabbit Proteintech IF 1:100 
LPAR1 10005280 rabbit Cyman chemicals WB 1:250 
LPAR1 sc-515665 mouse Santa Cruz IF 1:100 
      




name clone ID targeting sequence vector company 
shIFT88#1 V3LHS_338157 GGAATAACACTGACCACCT pGIPZ Dharmacon 
shIFT88#2 V3LHS_338155 AGCATCTGAATACTGACCA pGIPZ Dharmacon 
shKif3B#1 V3LHS_644788 TTGCTAGTCTCTTCTCTCA pGIPZ Dharmacon 
shKif3B#2 V3LHS_635533 ATCTCATCTTCATCCTGCA pGIPZ Dharmacon 
     





name sequence company 
BamHI-
LPAR1 































   












Study 2: The role of KIF2C/AURKA signaling in cilia loss and progression of 
glioblastoma. 
 






The primary cilium is a ubiquitous organelle presented on most human cells. It serves 
as a crucial signaling hub for multiple pathways including growth factor and G-protein 
coupled receptors. Loss of primary cilia was observed in various cancers, however, the 
implications of this event are unclear. Our long-term goal is to delineate the molecular 
mechanism of primary cilia disassembly under normal and pathological conditions and 
determine if the loss of the cilium is required for cancer progression. Aurora kinase A, a 
common proto-oncogene often overexpressed in GBM, initiates rapid cilia disassembly, 
but the downstream effectors of this pathway still have not been found. One of the 
potential AURKA effectors is the motor protein KIF2C, known to directly destabilize 
microtubules. AURKA can phosphorylate KIF2C on multiple sites during mitosis, 
however, nothing is known about AURKA and KIF2C interaction in non-mitotic cells. We 
found that KIF2C overexpression is triggering cilia disassembly in AURKA dependent 
manner, and are focusing on elucidating the molecular mechanism of the KIF2C driven 
cilia disassembly. Phosphorylation of KIF2C on S715 by AURKA was reported to 
enchance spindle pole microtubule targeting. Both spindle pole and axonemal 
microtubules are highly post-translationally modified, thus our central hypothesisis that 
AURKA-dependent phosphorylation of KIF2C on S715 leads to increased affinity towards 
post-translationally modified microtubules (acetylated and/or detyrosinated), and cilia 





Glioblastoma multiforme (GBM) is one of the most deadly cancers for which no 
effective treatment strategy currently exists. The primary cilium is a ubiquitous 
microtubule-based organelle that protrudes from the apical surface of most human cells 
serving as a cellular antenna for signal transduction and is an important regulator of 
mitosis. Cilia are lost in many types of cancer including GBM (1-6). The importance of 
cilia loss for cancer progression is largely unknown, although several attempts to rescue 
ciliation in cancer cells reveal the therapeutic benefit behind primary cilia restoration (7, 
8). The long-term goal of this study is to delineate the molecular mechanism of primary 
cilia disassembly under normal and pathological conditions and determine if the loss of 
cilium is required for cancer progression. This knowledge is critical for the development 
of new therapeutic strategies to prevent and eradicate tumor growth. Aurora kinase A 
(AURKA or AurA), a common proto-oncogene that is often overexpressed in GBM (9-12), 
initiates rapid cilia disassembly (7, 13), but the downstream effectors of this pathway have 
still not been found. One potential AURKA effector is the motor protein KIF2C, known to 
directly destabilize microtubules. KIF2C and its family member KIF2A were shown to 
promote cilium disassembly upon overexpression (14). KIF2C is phosphorylated by 
AURKA, which promotes its localization to highly post-translationally-modified spindle 
pole microtubules (15). Axonemal microtubules bear similar post-translational 
modifications as spindle pole microtubules and are usually detyrosinated (16). 
Interestingly, KIF2C has decreased activity towards detyrosinated microtubules (17), 
thus, the central hypothesis of this study is that AURKA-dependent phosphorylation of 
KIF2C leads to a change in substrate preference and cilia disassembly, resulting in an 
increase in cell proliferation and tumor progression. Rescue of ciliation will inhibit 
proliferation, disease progression, and also potentially, recurrence. This hypothesis was 
tested through the execution of the following aims: 
Aim #1: Determine the mechanism/s of KIF2C-driven deciliation. The working 
hypothesis is that AURKA phosphorylation promotes KIF2C translocation from the 




Aim #2: Determine the therapeutic benefits of combination therapy of KIF2C depletion 
and AURKA inhibition in the treatment of glioblastoma in patient-derived xenograft (PDX) 
models. The hypothesis is that the combination of KIF2C depletion and inhibition of 
AURKA will synergistically increase the incidence of primary cilia in cancer cells, as well 
as decrease tumor growth and potentially, recurrence. The rationale for the proposed 
work is that it will elucidate new mechanisms driving cilia disassembly, provide insight 
into the critical role of the primary cilia in cancer progression, and reveal new strategies 
for a targeted treatment of cancer.  
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Materials and methods 
Cell lines and reagents 
Human astrocytes isolated from human cortex (1800) were obtained from ScienCell 
Research Labs and maintained in DMEM/F12 supplemented with 10% heat-inactivated 
FBS, Antibiotic-Antimycotic (ThermoFisher), and 10 μg/ml of gentamycin (MP 
Biomedicals). Cells were propagated and cryopreserved at passage 2; for all studies, 
cells were not passaged more than 10 times or 8 weeks, and no authentication or 
mycoplasma testing were performed. For immortalization, primary astrocytes at passage 
5 or 6 were cultured until 50–75% confluency and transfected with SV40 large T-antigen 
construct (18) followed by selection with 500μg/ml G418 (Sigma) until resistant colonies 
were formed. RPE1 hTert cells were obtained from ATCC and cultured according to 
ATCC recommendations. U87MG and U373MG were a kind gift from Dr. Daniel C. Flynn 
and were also maintained according to ATCC recommendations. GBM6 and 12 PDXs 
(19) were kindly provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN) through a 
shared MTA agreement, and no authentication or mycoplasma testing were performed. 
PDXs were used for cell culture isolation as previously described (20). A list of antibodies 
and their used applications is outlined in Table 1. shRNA constructs were obtained from 
Dharmacon and are outlined in Table 2. All primers were purchased from IDT 
Technologies, the sequences of which are reported in Table 3. MLN8237 (Selleckchem) 
and Tubastatin A (Selleckchem) were also used. 
 
Western blotting 
Western blotting was performed using standard procedures (21). Primary antibodies 
that were used are outlined in Table 1. Secondary anti-mouse and anti-rabbit HRP-
conjugated antibodies (Jackson ImmunoResearch Labs) were diluted 1:10,000 followed 
by chemiluminescence-based detection with HyGLO™ (Denville Scientific). Bands were 
quantified using the digital electrophoresis documentation and image analysis software 
GeneTools (Syngene Corp.) with signal intensity normalized to α-tubulin. 
 
Immunofluorescent cell analysis 
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Cells were processed as previously described (13). Primary antibodies that were used 
are outlined in Table 1. Secondary antibodies included AlexaFluor 488, 555, and 647 
(ThermoFisher). Images were captured using a standard setting by an LSM510 confocal 
microscope (Zeiss) (21). All images represent whole-cell 3D reconstructed projections 
with 0.4μm steps. All quantifications were done using ImageJ (NIH). 
KIF2C cloning and cell lines generation 
KIF2C cDNA was purchased from PlasmID, PCR-amplified, and cloned into pEGFP 
(Clontech) vector between EcoRI and XhoI restriction sites. For inducible expression, 
EGFP-KIF2C fusion cDNA was cloned into pLUTZ lentivirus vector between AgeI and 
XhoI restriction sites (22). All constructs were validated by sequencing. 
Lentiviral particles were produced as previously described (13). Cells were infected 
and selected with correspondent antibiotics until stable clones were formed. 
 
Cell growth/proliferation analysis 
Cell growth rate was determined using semi-automated cell counting in ImageJ (NIH). 
Cells were plated at 1x104 cells per well and grown in the specified conditions for five 
days, fixed with methanol, and stained with Hoechst33342. Four random 10x fields per 
well were analyzed with at least three replicates per independent experiment; each graph 





KIF2C overexpression drives cilia disassembly in an AURKA-dependent 
manner. 
To test whether overexpression of KIF2C can cause loss of primary cilium, we 
generated RPE1-hTert and human immortalized astrocytes with inducible overexpression 
of GFP-tagged KIF2C. In both cell lines, overnight induction of KIF2C expression under 
ciliated, serum pre-starved conditions resulted in robust disassembly of primary cilia 
(Fig.1A, B). To test if cilium disassembly was KIF2C dose-dependent, time course 
experiments with limited KIF2C induction times were performed. The time course 
experiment revealed robust KIF2C dose-dependent disassembly of primary cilia (Fig.1C-
D). 
To test if AURKA plays a role in KIF2C-driven cilia disassembly, a small molecule 
inhibitor highly specific for AURKA called MLN8237 was used. Inhibition of AURKA and 
simultaneous induction of KIF2C significantly attenuated KIF2C-driven cilia disassembly 
(Fig.1E), suggesting that AURKA activity is required. Interestingly, KIF2C was noted to 
be present inside the primary cilium in several cells, and its presence was associated with 
decreased acetylated tubulin staining in the same area (Fig.1F). These data argue that 
KIF2C enters primary cilium prior to disassembling it. 
 
Ciliated cells are likely to be more a differentiated cell population within GBM. 
GBM tumor cells have decreased ciliation, but nevertheless up to 10% of GBM tumor 
cells possess primary cilia in vivo (23). This was confirmed for two PDX-derived GBM 
primary cell lines GBM6 and GBM12 (Study 1); these cell lines represent classical and 
mesenchymal subtypes of GBM, respectively, and were chosen due to their high 
expression of AURKA and KIF2C and the worst prognosis. To test if the ciliated population 
of GBM cells had any associated phenotype, Sox2 and CD44 expression was analyzed. 
Sox2 is enriched in self-renewing neural progenitor cells (24), and its loss in GBM tumor-
initiating cells causes abrogation of proliferation and tumorigenicity (25). CD44 is highly 
enriched in neural stem cells (26).The ciliated population of both GBM6 and 12 had only 
about 5% CD44-positive and 60% Sox2-positive cells, versus 40% and 80% in non-
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ciliated cells, respectively (Fig.2A-C), suggesting that this population is more 
differentiated and less proliferative. 
 
Depletion of KIF2C or inhibition of AURKA inhibit GBM cell proliferation and 
restore ciliation. 
To test if KIF2C has any effect on the proliferation of GBM cells, we generated U87MG 
cells with stable shRNA-driven depletion of KIF2C (Fig.3A). All cell sublines had at least 
an 80% depletion of KIF2C, and proliferated significantly slower compared to the control 
cell line (Fig.3B).Since AURKA activity is required for KIF2C-driven cilia disassembly, it 
was tested whether the inhibition of AURKA can restore ciliation. Inhibition of AURKA for 
24h with 50nM of MLN8237 was sufficient to cause a twofold increase in the ciliation of 
U87MG cells (Fig.3C) and also inhibit proliferation (Fig.3D). In PDX-derived GBM primary 
cells, incubation with MLN8237 for 24h was sufficient to increase ciliation of GBM6 cells 
up to 60%, as compared to 10-20% in the DMSO control group (Fig.3E). Interestingly, 
there were no changes in the total number of mitotic figures, however, half of the mitotic 
figures in MLN8237-treated cells represented characteristic abnormalities such as 





Validation of GFP-KIF2C data with untagged KIF2C. 
Data obtained from this study indicates that overexpression of GFP-KIF2C is sufficient 
to induce cilia disassembly (Fig.2), however, the level of overexpressed protein is much 
higher than the endogenous KIF2C level (Fig.2C). This can be explained by decreased 
depolymerization activity of EGFP-KIF2C (27) or the potential suppression of EGFP-
KIF2C cilia entry due to size exclusion (28). To address this issue, KIF2C cDNA was 
cloned into pLUTZ vector between EcoRI and XhoI restriction sites, allowing for the 
inducible expression of KIF2C without a tag. Utilization of this construct will allow the 
confirmation of previously obtained results, and clarify if KIF2C triggers cilia disassembly 
in a more physiological range. It is expected that lower levels of KIF2C trigger cilia 
disassembly, as well as more abundant KIF2C entry into the cilium. 
 
Evaluating the effects of S715 phosphorylation on KIF2C activity in vivo. 
To test whether phosphorylation status of KIF2C at the S715 site has an effect on cilia 
disassembly, we generated a series of KIF2C mutants: KIF2C-S715A (phosphor-dead), 
KIF2C-S715E (phosphor-mimicking) and KIF2C-KVD (microtubule disassembly-impaired 
(29)) in pLUTZ vector (Fig.4A). Utilization of these constructs will allow for evaluation if 
S715 phosphorylation effects the ability of KIF2C to disassemble primary cilia. It is 
expected that KIF2C-S715E will be more effective in cilium disassembly than KIF2C-wt, 
while KIF2C-S715A will be less effective in cilium disassembly than KIF2C-wt. KIF2C-
KVD will be utilized as negative control, since its overexpression is not expected to 
produce any effect on primary cilia. In addition, since KIF2C-KVD is supposed to be 
targeted to the cilium as well as KIF2C-wt, it is expected to see accumulation of KIF2C-
KVD at the tip/along the primary cilium upon overexpression. 
 
Evaluating the effects of S715 phosphorylation on KIF2C depolymerization 
activity in vitro. 
To test whether the phosphorylation status of KIF2C at the S715 site has an effect on 
in vitro microtubule depolymerization activity, cDNA for KIF2C wt, KIF2C S715A, S715E 
and KVD) was cloned in pcDNA3.1 6His-Flag vector (Fig.4B). This system allows to 
79 
 
express KIF2C and the mutants in HEK293T cells (Fig.4C). Future plans call for purifying 
the indicated proteins and using them for in vitro microtubule depolymerization assays 
(30). It is not expected to see any difference in depolymerization activity between KIF2C-
wt, KIF2C-S715A, and KIF2C-S715E, since tubulin available on the market consists of a 
mixture of tyrosinated and detyrosinated isoforms. To evaluate the substrate preference 
of KIF2C and its mutants, tyrosinated and detyrosinated tubulin dimers will be purified 
using previously described methodology (31). In experiments with tyrosinated tubulin, it 
is expected to see strong disassembly with KIF2C-wt, KIF2C-S715A, and KIF2C-S715E, 
while detyrosinated tubulin is predicted to be more resistant to KIF2C-wt and KIF2C-
S715A (17), but more sensitive to KIF2C-S715E (15). 
 
Evaluating the effects of KIF2C and AURKA depletion on the ciliation status of 
GBM PDXs in vivo and in vitro. 
To test whether depletion of KIF2C can restore ciliation in GBM PDXs, previously 
validated shRNA against KIF2C (Fig.3) will be subclonedfrom pGIPZ vectors into pTRIPZ 
vectors according to the manufacturer protocol to allow for inducible KIF2C depletion. 
Inducible shRNA against KIF2C will be introduced in GBM6 and GBM12 primary cultures 
and selected with puromycin. Selected cells will be injected into NSG mice for PDX 
amplification as described previously (20). Amplified PDXs will be validated for KIF2C 
depletion and used for in vivo and in vitro assessment of ciliation and proliferation. It is 
expected that primary cilia in GBM PDXs will be restored and severely suppress 
proliferation both in vitro and in vivo. Since the study data indicates that KIF2C-driven cilia 
disassembly is AURKA dependent (Fig.1E), inhibition of AURKA in conjunction with 
KIF2C depletion will be tested for their combined ability to restore ciliation and inhibit 
cancer cell proliferation. It is expected that better primary cilia restoration will occur with 
combination of AURKA inhibition and KIF2C depletion than with KIF2C depletion alone, 
since AURKA activation can initiate HDAC6-dependent cilia disassembly (13). 
 
Development of small molecule inhibitor for KIF2C. 
To develop an anti-KIF2C specific inhibitor, virtual screen of compounds was 
performed utilizing the publicly available crystal structure of the KIF2C motor domain 
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(https://www.ncbi.nlm.nih.gov/Structure/pdb/2HEH). The 11 compounds (Table 4) with 
the highest fitting scores from this screen will be utilized in in vitro microtubule 
depolymerization assays. The compounds with the best ability to inhibit KIF2C-driven 
depolymerization will be tested further for their ability to inhibit KIF2C-driven cilia 
disassembly in cells, along with their effect on cell viability. Compounds showing the best 
results in these assays will be tested in their ability to restore primary cilium and suppress 




Loss of the primary cilium seems to have a significant role in maintaining a highly 
proliferative phenotype in cancer (7, 8). At the same time, inhibition of primary cilia 
formation does not play a significant role in GBM tumor cell proliferation both in vitro and 
in vivo (27), and moreover, these findings argue that these cells are more differentiated 
(Fig.2). Targeting cancer cells in order to restore primary cilia is therefore expected to 
dampen proliferation and force re-differentiation of the cancer cells. Currently, the exact 
machinery participating in the disassembly of primary cilia has remained unknown, but 
this study establishes that KIF2C can enter primary cilium and promote disassembly in 
an AURKA-dependent manner. Targeting of either KIF2C or AURKA significantly affects 
proliferation of cancer cells. Elucidation of AURKA and KIF2C interactions that help 
promote primary cilia disassembly will allow for the development of new targeted 
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Fig. 1. KIF2C overexpression drives cilia disassembly in an AURKA-dependent 
manner. 
(A) Representative image of RPE1-hTert cells with (left-bottom corner) and without 
overexpression of GFP-KIF2C, stained for acetylated α-tubulin (AcTub, cilium marker) 
and KIF2C; scale bar – 10μm. Arrow indicates primary cilium. (B) Quantification of cilium 
in cells with (Dox+) without (Dox-) induction of EGFP-KIF2C expression as in (A) upon 
24h of serum starvation; 300 cells total, 100 cells in each of 3 independent experiments; 
Student’s t-test, p<0.05. (C) Western blot of KIF2C in RPE1-hTert cells after 24h of serum 
starvation and induction of EGFP-KIF2C expression for the indicated number of hours. 
(D) Quantification of cells forming primary cilium upon induction of GFP-KIF2C expression 
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for the indicated number of hours as in (C); 300 cells total, 100 cells in each of 3 
independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (E) 
Quantification of cells forming primary cilium as in (B) upon induction of GFP-KIF2C 
expression for 16h in the presence or absence of 50nM MLN8237; 300 cells total, 100 
cells in each of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc 
test, p<0.05. (F) Representative image of the primary cilium in human astrocytes after 
48h of serum starvation, followed by 8h induction of GFP-KIF2C expression, stained for 
acetylated α-tubulin (AcTub, cilium marker) and KIF2C; scale bar – 10μm. Arrow indicates 





Fig. 2. Stem-cell/differentiation marker status of ciliated cells is different from 
cells without primary cilia. 
(A) Representative image of GBM6 and GBM12 cells with and without primary cilia 
stained for acetylated α-tubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body 
marker), and CD44 (neural stem-cell marker); scale bar – 10μm. (B) Quantification of 
CD44+ cells as in (A); 200 cells total, 100 cells in each of 2 independent experiments; 
Student’s t-test, p<0.05. (C) Quantification of Sox2+ cells; 200 cells total, 100 cells in each 





Fig. 3. Effects of KIF2C depletion and inhibition of AURKA on GBM cell 
proliferation and ciliation. 
(A) Western blot of KIF2C in U87MG cells stably-expressing shRNA against KIF2C. 
(B) Growth curve of U87MG cells as in (A); slopes of the fitted lines significantly different 
in F-test, * p<0.05 (C) Quantification of cilium in U87MG cells treated with 50nM MLN8237 
or 15μM Tubastatin A; 500 cells total, 250 cells in each of 2 independent experiments; 
one-way ANOVA with Dunnett’s post hoc test, p<0.05. (D) Growth curve of U87MG cells 
as in (C); slopes of the fitted lines significantly different in F-test, * p<0.05. (E) 
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Quantification of GBM6 cells forming primary cilium in the presence of 50nM MLN8237; 
300 cells total, 100 cells in each of 3 independent experiments; Student’s t-test, p<0.05. 
(F) Representative image of the mitotic figures in GBM6 cells as in (E). Top image depicts 
normal mitotic figure, and bottom image depicts abnormal, monopolar mitotic figure; 
stained for acetylated α-tubulin (AcTub, cilium marker) and DAPI; scale bar – 10μm. (G) 






Fig. 4. KIF2C cloning and protein production. 
(A) Map of pLUTZ KIF2C construct.(B) Map of pcDNA3.1 6xHis-Flag KIF2C construct. 
(C) Western blot of 6xHis-Flag-KIF2C expressed in HEK293T cells. Cells were lysed in 












T6793 mouse Sigma IF 1:1000 
gamma 
tubulin 
sc-7396 goat Santa Cruz IF 1:500 
alpha 
tubulin 
16199 mouse Sigma WB 1:40000 
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name clone ID targeting sequence vector company 
shKIF2C#1 V3LHS_357508   AAACTACTGTCATACTCCT pGIPZ Dharmacon 
shKIF2C#2 V3LHS_357509 TGGAGTTGACGGATCTCCG pGIPZ Dharmacon 




name sequence company 
EcoRI-Kif2C ATTGAATTCATGGCCATGGACTCG IDT Technologies 





















































The primary cilium is a crucial organelle for the transduction of multiple signaling 
cascades (1-3). Loss of primary cilia is associated with an increase in cell proliferation in 
some cell types (3, 4), while suppressing cell proliferation in others (5, 6). In the majority 
of cancer types, including GBM, the length and number of primary cilia are significantly 
reduced or lost (7-10). Overall, the studies documented in this dissertation present 
multiple novel insights into the role of the primary cilium in the regulation of normal and 
cancer cell proliferation and in the mechanisms of cilia disassembly. In Study 1, it was 
demonstrated that the loss of primary cilia promotes proliferation of human astrocytes in 
a growth factor-dependent manner. For the first time, it was demonstrated that spatio-
temporal characteristics of the cellular response to growth factors are drastically altered 
upon the loss of primary cilia. Previously, PDGF-AA signaling through PDGFRαα was 
reported to be lost in deciliated fibroblasts (11), and IGF1R signaling was significantly 
reduced (12), thus an increase in proliferation upon the loss of primary cilia is a somewhat 
unexpected phenomenon. Other RTKs such as EGFR, FGFR, and Tie1/2 were noticed 
to localize to primary cilia (13-17), but the significance of this is unknown. In addition, 
different GPCRs can accumulate in the primary cilium (18, 19) along with their 
downstream signaling components (20, 21). Therefore, loss of cilia can interfere with 
multiple signaling cascades of various modalities, and systematic studies of signaling 
alterations are very scarce. In Study 1, LPA was established to be the main non-peptide 
growth factor responsible for the increased proliferation of astrocytes with disrupted 
ciliogenesis. For the first time, scrutinous analysis of the hyperproliferative phenotype in 
cells with an engineered loss of cilia was able to establish the underlining mechanism for 
increased proliferation. It was found that LPA-LPAR1 signaling is regulated by primary 
cilia. Loss of primary cilia promotes redistribution of LPAR1, which is normally localized 
to the cilium, and streamlines signaling through Gα12/Gαq, thus increasing proliferation. 
Gα12 and Gαq activation were previously reported to be implicated in cancer cell 
proliferation and cancer progression (22, 23). Furthermore, the LPAR1-Gα12 module 
specifically was reported to drive ovarian cancer cell proliferation (24). These findings 
suggest that primary cilia restricts LPA-LPAR1-driven Gα12/Gαq activation. Loss of cilia in 
GBM cells highjacks LPA signaling to maintain a highly proliferative phenotype, rendering 
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them sensitive to inhibition of LPAR1. Utilization of a nanoparticle-based delivery of 
Ki16425, a small molecule inhibitor of LPAR1-3, as a monotherapy significantly 
decreased GBM growth in vivo. These results clearly indicate that inhibition of LPA 
signaling is a viable therapeutic option for GBM control in addition to standard care, 
especially in light of the implication of LPA in proliferation and migration/invasion (25, 26). 
Currently, the standard of care for GBM patients includes surgical resection of the tumor 
and a combination of radiation and chemotherapy (27). Unfortunately, the majority of 
patients experience recurrence of the disease within several months (28). Novel 
approaches in immunotherapy of GBM seem to be promising, but sustained responses 
are still rare (29). In part, this may be due to the prolonged lag period between the initiation 
of therapy and the tumor response (30), thus utilization of a tumor growth suppression 
agent in combination with an immunotherapeutic approach could be beneficial. Further 
studies are required to establish the possibility of combining LPAR inhibitors with 
conventional or immuno-based therapies. However, two LPAR inhibitors were recently 
used for clinical trials. BMS-986020, an LPAR1 inhibitor, is in Phase 2 clinical trials for 
idiopathic pulmonary fibrosis (NCT01766817); and SAR100842, an LPAR1 and 3 
inhibitor, is in Phase 2 clinical trials for systemic sclerosis (NCT01651143). If the results 
of the current study can be replicated utilizing these compounds, GBM patient survival 
could be significantly improved, and disease control would become much easier. Based 
on Study 1’s findings, it would be expected to see a substantial increase in recurrence-
free survival upon inhibition of LPA signaling in addition to the current standard of care. 
Since loss of primary cilia alters a great number of signaling pathways, restoration of 
primary cilia in cancer cells could potentially restore proper signaling and induce re-
differentiation. So far, several attempts were made to restore cilia in cancer cells, and 
results have been very promising (4, 31). However, since the mechanisms of cilia 
disassembly are still not fully understood, it is difficult to pursue. Thus, it is crucial to 
delineate the pathways involved in cilium loss. Study 2 focused on the role of KIF2C in 
the disassembly of cilia. It was found that KIF2C can enter and disassemble primary cilia 
in an AURKA-dependent manner. The differentiation/stem marker status of ciliated GBM 
cells was evaluated, which confirmed that the cilium is likely to promote re-differentiation 
along with halting proliferation. Finally, it was established that targeting of KIF2C and 
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AURKA drastically decreases proliferation of GBM cells, and moreover, AURKA inhibition 
can robustly restore primary cilia in these cells. AURKA is well known as a master 
regulator of cilia disassembly (32), as well as being an important mitotic regulator (33). 
Inhibition of AURKA, therefore, can suppress tumor growth in two ways: first, through 
direct inhibition of mitosis, and second, through restoration of the primary cilia. KIF2C is 
also involved in progression through mitosis, however depletion of KIF2C in non-
transformed cells tends to generate a much milder phenotype than in cancer cells (34), 
indicating that KIF2C inhibition can potentially yield very little side effects. Further studies 
are required to elucidate the exact mechanism of AURKA–KIF2C cooperation in driving 
cilia disassembly. Unveiling the mechanisms of cilia disassembly in cancer cells will allow 
for the development of novel approaches for anti-cancer therapy. Restoration of primary 
cilia in cancer cells is expected to suppress proliferation and initiate re-differentiation, thus 
allowing for robust and prolonged disease control. 
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1 Waterfront Pl, Morgantown, WV 26501. 








Graduate studen 10/12/2012-11/13/2017 
West Virginia University, 
Department of Biochemistry 
1 Medical Center Drive, HSC-S, 
MBRCC-2813, Morgantown, WV, 26506 
Tel: 304-293-0500 
Research subject: 
Investigating the role of primary cilia and 
associated signaling cascades in 
maintaining highly proliferative 
phenotype of glioblastoma, using 
primary cells and patient derived 
platforms. Devising novel therapeutic 
strategies to treat glioblastoma, based 
on inhibition of the abnormal growth 
factor signaling initiated by loss of 
primary cilia. 
Supervisor: Elena N Pugacheva, Ph.D 
Associate Professor, Biochemistry and 
WVU Cancer Institute, 
Adjunct Assoc.Professor Radiation 
Oncology 
Co-leader of Breast Cancer Research 
Program 
PDX Core Facility Director HSC, 
West Virginia University School of 
Medicine 
Health Sciences Center 
1 Medical Center Drive, Rm.2832, 




Research Scholar 09/28/2010-10/12/2012 
West Virginia University, 
Department of Biochemistry 
1 Medical Center Drive, HSC-S, 
MBRCC-2813, Morgantown, WV, 26506 
Tel: 304-293-0500 
Research subject: 
Identification of novel targets of AURKA, 
involved in primary cilia disassembly 
during cell cycle. 
Determine the role of NEDD9 adhesion 
adaptor protein in invasion of breast 
cancer cells in vitro and in vivo using cell 
lines and mouse model, investigating the 
Supervisor: Elena N Pugacheva, Ph.D 
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Associate Professor, Biochemistry and 
WVU Cancer Institute, 
Adjunct Assoc.Professor Radiation 
Oncology 
Co-leader of Breast Cancer Research 
Program 
PDX Core Facility Director HSC, 
West Virginia University School of 
Medicine 
Health Sciences Center 
1 Medical Center Drive, Rm.2832, 
Morgantown, WV, 26506-9300. 
Tel: (304)293-5295 
 
role of NEDD9 in supporting MMP14 
recycling and activity. 
 
Junior scientist 2009-06/01/2010 
Pavlov Institute of Physiology, 
6 Nab. Makarova, 199034 
St.Petersburg. Russia 
Tel.: 7(812) 3280701 
Research subject: 
Investigating the interaction between 
nervous and immune systems; TLR4 
expression in enteric neurons following 
LPS challenge. Supervisor: Soukhova Galia, PhD 
Senior Scientist, 
Pavlov Institute of Physiology, 






Undergradute student-researcher 2006-2009 
Institute of Experimental Medicine, 
12 Academic Pavlov str, 
St.Petersburg, Russia, 197376 
Tel.: 7(812)2346868 
Research subject: 
Interaction between nervous and 
immune systems; studies dedicated to 
preproorexin gene expression in the 
hypothalamic cells of rats after LPS 
challenge. 
Supervisor: Novikova Natalia, Ph.D. 
Senior Staff Scientist, 
Institute of Experimental Medicine, 
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12 Akademic Pavlov str, 






AWARDS AND HONORS 
Award Years 
BSc diploma with honors 2008 
MSc diploma with honors 2010 
Van Liere Memorial Convocation and HSC Research Day, 




Role Society Years 
Associate 
Member 





Bacterial cell culture: 
Preparation and propagation of cultured bacteria, transformation of bacteria cells. 
Preparation of chemically competent cells suitable for molecular cloning (DH5α) and 
protein production (BL21). 
Mammalian cell culture: 
Mammalian cells (including normal epithelial, fibroblast, astrocytes and cancer cell lines), 
generation of stable transgene expressing cell lines, cell lines with shRNA or 
CRISPR/Cas9-based depletion/knockout. Viral stock preparation and infection. Cell 
proliferation, adhesion and invasion assays in 2D and 3D matrix cultures. 
Molecular biology: 
PCR techniques, gel electrophoresis, genomic/plasmid DNA and RNA purification, site 
directed mutagenesis, DNA ligation/molecular cloning, expression and purification of 
proteins from bacterial and mammalian cells, in vitro kinase assay, protein labeling, 
immunoprecipitation, Western blotting, enzyme linked immunosorbent assay (ELISA), 
fluorescence-activated cell sorting (FACS). Design of custom lentivirus-based vectors. 
Imaging: 
Live cell imaging systems: confocal and bright field microscopy, confocal data analysis 
software and 3D deconvolution, imaging of primary cilia and vesicular transport. Focal 
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adhesion and actin dynamics using fluorescently labels proteins. Fluorescence recovery 
after photobleaching (FRAP) and subsequent data analysis. 
In vivo imaging techniques: ultrasound imaging using VeVo system, luciferase based 
xenograft imaging using IVIS system, contrast enhanced MRI using ICON system; and 
subsequent data analysis. 
Animal models: 
Solid knowledge of rodent physiology, animal handling, particularly laboratory rats and 
mice; maintenance of mouse colony, including managing transgenic mice strains; breast 
and glioblastoma xenograft tumor implantation, tumor bearing animal care and tumor 
burden evaluation. Rodent surgeries: estrogen pellets implantation/removal, tumors 
implantation/resection (subcutaneous and orthotopic), stereotactic guided intracranial 
injections. Behavioral evaluation in mice, including Morris water maze and open field test. 
Experienced in animal studies protocol development, management and review. 
Patient derived tumor models: 
Handling patient samples, cataloging and processing new samples; surgical implantation 
of the patient tumors, maintenance and support of patient-derived xenograft colony 
maintenance. Designing and running of the therapeutic compound screens in patient-
derived xenograft transplanted mice. 
Large data analysis: 
Experienced with TCGA data mining and analysis, as well as RNAseq data analysis and 
interpretation (as part of the bioinformatics workshop class by Dr. Peter Stoilov) 
Miscellaneous: 
Proficient in supplies ordering, lab maintenance, teaching of new students. Project 
development experience, grants and manuscripts writing and preparation for publication. 
Other Skills: 
Proficient with Microsoft Office package, Vector NTI, ImageJ, Adobe Photoshop/GIMP 
and Illustrator/InkScape, GraphPad Prism, basic knowledge of R. 
 
RECOMMENDATIONS 
For further recommendations, please, contact: 
Elena Pugacheva, PhD 
 Associate Professor, Biochemistry and WVU Cancer Institute, 
 Adjunct Assoc.Professor Radiation Oncology 
 Co-leader of Breast Cancer Research Program 
 PDX Core Facility Director HSC, 
 MBRCC 2813, 1 Medical Center Dr., 
 Morgantown, 26506, WV, USA 
 Tel: 304-293-5295, epugacheva@hsc.wvu.edu 
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Michael D. Schaller, PhD 
 Chairman, Department of Biochemistry, WVU 
 HSCN 3124, 1 Medical Center Dr., 
 Morgantown, 26506, WV, USA 
 Tel: 304-293-9514, mschaller@hsc.wvu.edu 
Michael Ruppert, MD/PhD 
 Professor, Department of Biochemistry, WVU, 
 Jo and Ben Statler Eminent Scholar & Chair in Breast Cancer 
 Research 
 Co-Director, Program in Breast Cancer Research, MBRCC 
 BMRC-Erma Byrd 212, 1 Medical Center Dr., 
 Morgantown, 26506, WV, USA 
 Tel: 304-293-5246, mruppert@hsc.wvu.edu 
Peter Stoilov, PhD 
 Associate Professor, Department of Biochemistry, WVU, 
 HSCN 3131 C, 1 Medical Center Dr., 
 Morgantown, 26506, WV, USA 
 Tel: 304-293-6334, pstoilov@hsc.wvu.edu 
Karen Martin, PhD 
 Research Assistant Professor, Department of Microbiology, 
 Immunology & Cell Biology, WVU, 
 Research Associate Professor, Department of Neurobiology and 
 Anatomy, WVU 
 Scientific and Technical Director, Microscope Imaging Facility, 
 WVU 
 Scientific and Technical Director, Animal Models & Imaging 
 Facility, WVU 
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 BMRC-Erma Byrd 210, 1 Medical Center Dr., 
 Morgantown, 26506, WV, USA 
 Tel: 304-293-6965, kamartin@hsc.wvu.edu 
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